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GEnERAL InTRODuCTIOn
Chronic pain
Chronic pain is defi ned by the International Association for the Study of Pain (IASP) as pain 
without apparent biological value that has persisted beyond the normal tissue healing time 
(usually taken to be 3 months).1 Pain is a unique, individual and subjective experience that 
encompasses biological, psychological, and social factors. According to the World Health Orga-
nization, chronic pain is a chronic disease in its own right. Its prevalence is reported to be one 
in fi ve adults around the world.2-4 Chronic pain is a major source of personal suff ering, including 
a negative impact on quality of life, sleeping and functionality.2 Furthermore, it constitutes a 
major economic burden for society. In the United States alone, the economic costs associated 
with chronic pain were estimated in 2010 to be between $ 560-635 billion annually.5
Like other chronic diseases, chronic non-malignant pain is managed primarily in primary 
care, where it accounts for 20% of all patients evaluated. Only 5% of these patients reported 
having ever consulted a pain specialist.6 The treatment of chronic pain is challenging, and a 
considerable amount of patients report poor outcome.2,7 Chronic pain treatment frequently 
requires a multidisciplinary ‘bio-psycho-social’ approach, including physical rehabilitation and 
psychological support. However, pharmacotherapy is one of the cornerstones of pain therapy.8 
Analgesic medications are on top of the list of classes of drugs prescribed during physician 
consultations or emergency room visits.6 However, the eff ects of pain medication on chronic 
pain are variable and often not as good as desired. Placebo-controlled outcome studies for 
pharmacological approaches to chronic pain reveal that they provide, on average, a meager 
30% effi  cacy.9 The numbers-needed-to-treat (NNT) with the most eff ective monotherapy to 
achieve pain reduction of at least 50% are in the range of 2 to 4 meaning that on the aver-
age one patient in 2 to 4 has his/her pain halved.9 Several factors may account for the variable 
eff ects of pain treatment, including age, pharmacokinetic diff erences and pharmaco-genetic 
variability.10
Medication non-adherence
Another reason for the sub-optimal eff ect of chronic pain treatment may be that patients do 
not adhere to the prescription of the care provider. Adherence can be defi ned as “the extent 
to which a person’s behaviour corresponds with the agreed recommendations from a health 
care provider”.11 Poor medication adherence is relatively common. Studies in chronic conditions 
have shown consistently that 20 to 30 percent of medication prescriptions are never fi lled and 
that, on average, 50 percent of medications for chronic disease are not taken as prescribed. 
In developing countries, the rates are even higher.11 Non-adherence is a complex multifacto-
rial behaviour. Determinants include patient-related, provider-related and healthcare system-
related factors.12 Unintentional non-adherence, e.g. due to inability to schedule, administer 
or remember the treatment, is mostly related to the lack of patients’ capacity or resources 
CHAPTER 1
10
to adhere to prescribed therapy. Intentional adherence is a conscious decision that involves 
patient perception of necessity and concerns about prescribed therapy. Non-adherence to 
chronic therapy in general leads to poor health outcomes and increased health care costs.12,13 
The price of nonadherence is considerable. In the United States, estimated direct and indirect 
costs totaled $ 337 billion in 2013 due to otherwise-preventable hospital admissions, emer-
gency room visits, physician visits and medical tests.13 
The prevalence of non-adherence to chronic pain therapy has been reported to be consider-
able as well: 30 percent of patients used less medication, and 14 percent took more medication 
than prescribed.14 Underuse and overuse of medication are two separate patterns of non-
adherence that should be differentiated, as they have different causes and consequences. Non-
adherence to chronic pain medication has been associated with reduced treatment effects.15,16 
Although a causal relation has not been established, it seems plausible that ‘drugs don’t work 
in patients not taking them’.17 Furthermore, overuse of pain medication can inevitably lead to 
health care risks or even death. 
Apart from overuse of pain medication with an intention to control pain symptoms, opioid 
abuse and addiction to prescribed pain medications have been described to have reached epi-
demic proportions. Nearly half of all U.S. opioid overdose deaths involve a prescription opioid. 
In 2015, more than 15,000 people died there from overdoses involving prescription opioids.18 
Abuse and addiction have been classified in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5).19 They are considered separate entities from medication non-adherence, 
with separate risk factors and management strategies.20 However, the line between overuse on 
the one hand, and abuse or addiction on the other, may be thin.14
Interventions
The World Health Organization recognizes a definite need for action to improve medication 
adherence: “Increasing the effectiveness of adherence interventions may have a far greater im-
pact on the health of the population than any improvement in specific medical treatments”.11 As 
medication adherence is typically the result of a combination of patient, provider, health care 
system and policy factors, most of the effective interventions for chronic conditions in general 
were indeed multifactorial: over half were aimed at multiple targets and most had multiple 
components.21 In other words, no single “silver bullet” exists for medication adherence. Studies 
identifying the active ingredients of these complex interventions are lacking, making it difficult 
to reproduce them in clinical practice. In chronic pain management, there were no studies 
reporting successful interventions up to now. 
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AIMS AnD COnTEnTS Of ThIS ThESIS
The aim of the work presented in this thesis was to explore the concept of medication ad-
herence in chronic non-malignant pain patients in order to design eff ective interventions to 
improve pain medication adherence. 
Chapter 2 describes a systematic literature review of the prevalence and determinants of 
medication non-adherence. 
Chapter 3 presents the results of a prospective correlational study investigating the relation-
ship between knowledge and medication adherence in chronic non-malignant pain patients.
In chapter 4, the results of a randomized clinical trial investigating the eff ect of a standard-
ized medication-specifi c information video on pain medication adherence and treatment 
outcome are reported.
Chapter 5 describes the results of a randomized clinical trial investigating the eff ect of three 
follow-up strategies on medication adherence and treatment outcome.
Chapter 6 reports on the associations between patients’ beliefs about pain medication, 
medication adherence patterns and outcome parameters.
Chapter 7 presents the design of a theory-based adherence improving intervention using 
the COM-B model of behaviour.
Chapter 8 discusses the main fi ndings, addresses the study limitations, and considers vari-
ous implications for daily practice and future research.
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AbSTRACT
background
Chronic pain is commonly treated with analgesic medication. Non-adherence to prescribed 
pain medication is very common and may result in suboptimal treatment outcome. The aim 
of this review is to investigate the prevalence of medication non-adherence and to present 
determinants that may help identify patients at risk for non-adherence to analgesic medication.
Methods
A search was performed in PubMed and Embase with systematic approach including PRISMA 
recommendations. Individual risk of bias was assessed and systematic data extraction was 
performed.
Results
Twenty-five studies were included. Non-adherence rates to pain prescriptions ranged from 8 
to 62 percent with a weighted mean of 40 percent. Underuse of pain medication was more 
common than overuse in most studies. Factors that were commonly positively associated with 
non-adherence were dosing frequency, polymedication, pain intensity, and concerns about 
pain medication. Factors negatively associated with non-adherence were age, again pain 
intensity and quality of the patient-caregiver relationship. Underuse was positively associated 
with active coping strategies and self-medication, and negatively associated with perceived 
need for analgesic medication. Overuse was positively associated with perceived need, pain 
intensity, opioid use, number of prescribed analgesics, a history of drug abuse and smoking.
Conclusion
Non-adherence to analgesic medication is very common in the chronic pain population. The 
choice for pharmacological therapy should not only be based upon pain diagnosis, but should 
also take the risks of non-adherence into account. The value of adherence monitoring or adher-
ence enhancing interventions has to be investigated in future studies. 
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InTRODuCTIOn
Non-adherence to chronic medical therapy is reported to play a substantial role in the sub-
optimal effi  cacy of chronic disease treatments.1,2 Medication adherence in chronic disease, i.e. 
diabetes, hypertension, COPD and mental health care, has been studied extensively. In these 
populations, non-adherence to medication resulted in increased health care costs, morbidity 
and mortality.3 A meta-analysis of 569 studies reported an average non-adherence rate across 
diseases of 20,6%.3 Determinants of non-compliance as well as successful interventions have 
been presented to improve compliance and treatment outcome.2,4-10 
In chronic pain, there is a growing interest for the impact of non-adherence to pharmaco-
logical pain treatment as well. Chronic non-malignant pain is a common health problem that 
leads to disability as well as high medical and societal costs. Although chronic pain requires 
a multidisciplinary approach, pharmacological therapy remains a cornerstone of chronic pain 
treatment. Whereas over 60% of pain suff erers use medication to relieve their pain, this therapy 
is often not as eff ective as desired.11 Adherence research in chronic pain management has, due 
to increasing reports of prescription drug abuse, been primarily focused on identifi cation and 
prevention of opioid overuse, abuse and addiction.12, 13 This is due to the epidemic increase 
in prescription drug abuse and addiction problems since the 1990s, mostly described in 
North America. However, addiction and abuse, with their own recognized risk factors, should 
be considered phenomena diff erent from non-adherence. Abuse has a more compulsory 
character and deals with other issues than medication adherence. With regard to adherence, 
most deviations from physician instructions are omissions, i.e. underuse of medications.14,15 In 
a previous review, a mean of 29,9% of chronic non-malignant pain patients took less medica-
tion and 13,7% took more medication than prescribed.16 Although it seems obvious that drugs 
will not be eff ective in patients not taking them, it is still unknown whether improvement of 
medication adherence will result in improved outcome in chronic pain patients. Awareness of 
the incidence of non-adherence and knowledge of determinants of non-adherence may help 
prescribing caregivers to make decisions about pain treatments and follow-up strategies. The 
aim of this review is to provide an update on the prevalence of medication non-adherence 
in chronic non-malignant pain patients and to present determinants that may help identify 
patients at risk for non-adherence to analgesic medication.
METhODS
This review was conducted according to a predefi ned protocol containing inclusion criteria, 
outcome parameters and a data collection chart. The protocol has not been registered in a 
review database. Study selection, data extraction and quality assessment was performed by 
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two reviewers (LT and DLS) independently. Discrepancies were discussed until consensus was 
reached.
Literature search
We performed a literature search using Pubmed and Embase databases. We completed the 
database search on October 13, 2014. The keywords used in the Pubmed database were: (ad-
herence OR compliance OR misuse) AND chronic pain AND (medication OR drug). The search 
strategy in Embase was as follows: chronic pain’/exp OR ‘chronic pain’ AND (adherence:ab,ti OR 
compliance:ab,ti OR misuse ab,ti). Two independent reviewers screened citations and abstracts 
for relevance. Full text articles of relevant citations were retrieved and judged according to the 
inclusion criteria. Reference lists were screened for additional papers. If there was any doubt 
regarding the inclusion of a paper, the study was discussed until consensus was reached. 
Eligibility criteria
We included original reports of studies that described pain medication non-adherence in 
chronic non-malignant pain patients aged 18 years and older as an outcome measure quanti-
tatively. Retrospective, prospective and cross-sectional studies in English, German and Dutch 
literature were assessed for inclusion, regardless of their publication status. Articles reporting 
adherence to analgesics qualitatively were excluded in the study. Articles were also excluded if 
they reported adherence to anti-rheumatic medication that was primarily focused on modify-
ing disease activity. Studies focusing on aberrant opioid taking behavior including substance 
abuse, diversion, and illicit drug use without describing actual medication adherence quantita-
tively were excluded. Furthermore, reports describing the analyses of large databases of urine 
samples or pharmacy records instead of patient populations were excluded as well.
Data extraction
Duplicate data extraction was performed using a standardized checklist containing the follow-
ing variables: study design, year of publication, sample size, population, definition of adher-
ence, method of measuring adherence, non-adherence level and determinants associated with 
non-adherence. If a determinant was shown to be associated with adherence in one or more 
studies, other studies were screened for conflicting results (no association found) regarding this 
determinant. Finally, funding sources and conflicts of interest reported in the included studies 
were recorded.
Quality assessment
The methodological quality of the eligible studies was assessed at study level using an assess-
ment list based on recommendations from Sanderson, Tatt and Higgins.17 This quality assess-
ment checklist has been designed for use in observational adherence research and contains 
11 items concerning selection methods, measurement of variables, sources of bias, control 
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for confounding and appropriate use of statistics (Table 1).18 Given the fact that the results 
almost entirely concern longitudinal relationships between predictive factors and adherence 
(for which the Sanderson et al criteria were designed) we decided to use this list for quality 
assessment for all the studies, including the prospective studies and randomized trials. Two 
observers assessed the quality of the studies independently, and discrepancies were discussed 
Table 1. Quality assessment checklist for observational adherence studies constructed by Pasma et al.. Bold 
items indicate the ‘essential criteria’.
Appropriate methods for patient selection
1 Positive if the main features of the study population are described (sampling frame and 
distribution of the population by age and sex) 
2 Positive if the participation is >80% or if participation is 60–80% and non-response 
is not elective (data presented) 
Methods for Measuring Exposure and Outcome Variables
3 Positive if method for measuring adherence is reproducible
4 Positive if method for measuring adherence is valid (blood serum/urine measurements, 
MEMS, pharmacy records and a validated questionnaire are considered valid, patient 
questionnaire and/or interviews and healthcare provider assessment are considered as 
not valid)
5 Positive if method for measuring determinants is reproducible 
Appropriate Design-Specifi c Sources of Bias
6 Was serious recall bias reduced? (adherence <1 week) 
7 Was serious selection bias reduced? (by inviting consecutive patients/ representa-
tive sample)
Appropriate Methods to Control Confounding
8 Positive if the analysis is controlled for confounding (such as age/sex) or eff ect modifi ca-
tion
9 Positive if the eff ect of confounding is quantifi ed in analysis (univariate and multivariate 
analysis)
Appropriate Statistical Methods (Primary Analysis of Eff ect but Excluding Confounding)
10 Positive if quantitative measures of association are presented (such as r, β, OR), including 
95% CI’s and numbers in the analysis(totals)
11 Positive if the number of cases in the multivariate analysis is at least 10 times the number 
of independent variables in the analysis (fi nal model)
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and resolved. Each item answered with ‘yes’ received one point. Five items were considered as 
essential questions. Studies were considered to be of high quality if 4 out of 5 of the essential 
questions were answered with ‘yes’ and if the total score was 7 or higher. 
RESuLTS
The reviewing process is presented in figure 1. The Pubmed and Embase search retrieved 
2803 and 3990 citations, respectively. Eighty full-text articles were retrieved, 25 articles were 
included in this review.14, 19-42 Most articles were excluded because they focused on opioid 
abuse. The design and method of adherence measurement of the included studies are shown 
Pubmed: 2803 Embase: 3990 
Exclusion based on 
title or abstract
Articles retrieved n=73 
References meeting 
inclusion criteria n=7
n=80 
Not meeting inclusion 
criteria n=55 
- focus on opioid 
abuse n=19 
- urine sample 
database n=7 
- pharmacy 
database n=10
- prescription use 
not quantified 
n=10 
- population 
unclear or not 
representative 
n=4 
- other n=5Inclusion n=25 
n=56 n=52 
fig. 1. Flow chart of study selection.
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in table 2. Self-report was most frequently used to measure adherence, followed by structured 
interview, electronic monitoring, and urine screening, respectively (Table 2). Nine studies were 
performed in a population with chronic non-malignant pain in general 21,27,31-34,36,39,40, nine 
studies focused on chronic pain patients using opioids 14,25,26,30,35,37,38,41,42, two studies focused on 
chronic headache or migraine 19,23, two studies included patients with rheumatic diseases (an-
kylosing spondylitis, osteoarthitis) 20,22, two studies concerned fi bromyalgia 24,28 and one study 
concerned patients with diabetic neuropathy using SSRIs or gabapentin treatment (table 3).29 
Table 2. Study characteristics.
Author Year Design n Adherence measurement
Packard 19 1986 Prospective descriptive study 88 Interview
Weinberger 20 1991 Randomized clinical trial 439 Self report
berndt 21 1993 Prospective correlational study 99 Urine screening
De klerk 22 1996 Randomized controlled trial 65 MEMS
Mulleners 23 1998 Prospective observational study 29 MEMS
Sewitch 24 2004 Prospective correlational study 127 Self report (MMAS-4)
Manchikanti 25 2005 prospective comparative study 200 Urine screening
Ives 26 2006 Prospective cohort study 196 Urine screening/ pharmacy records
McCracken 27 2006 Cross sectional correlational study 220 Self report
Dobkin 28 2006 Prospective correlational study 121 Self report (MMAS-4)
Giannopoulos 29 2007 Randomized clinical trial 93 Interview and pill count, SSRI or gabapentin 
prescribed
navato 30 2009 Prospective observational study 105 Urine screening
Lewis 14 2010 Cross sectional correlational study 191 Structured interview
broekmans 31 2010 Cross sectional correlational study 281 Structured interview
broekmans 32 2010 Cross sectional correlational study 265 Self report
nicklas 33 2010 Cross sectional correlational study 217 Self report (medication adherence report scale)
Stern 34 2011 Cross sectional correlational study 1321 Self report (missed dose previous week)
Chang 35 2011 Cross sectional correlational study 21 Self report (MMAS-8)
Rosser 36 2011 Cross sectional correlational study 239 Self report (four questions)
bronstein 37 2011 Prospective observational study 41 Urine screening
Grattan 38 2012 Cross sectional study 1191 Structured interview
Timmerman 39 2013 Prospective observational study 96 Structured interview
Markotic 40 2013 Cross sectional correlational study 100 Self report (direct questioning and MMAS-4)
barth 41 2014 Cross sectional study 307 Self report
Mattelliano 42 2014 Retrospective study 120 Urine screening
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Prevalence
The reported rates of non-adherence in patients with chronic pain, including the definition 
used for non-adherence, are shown in table 3. Non-adherence rates ranged from 8 % to 62 % 
with a weighted mean of 40%. Six of the studies made clear distinction between medication 
under- and overuse.14,21,31,32,35,36 In most of these latter studies, underuse was more common than 
overuse.14,31,32,35,36 Another five studies only investigated underuse non-adherence.20,24,28,29,34 
From five studies measuring adherence by urine screening, only prescription underuse rates 
were used in this review. Rates of non-prescribed or illicit drug use, or other aberrant drug 
taking behaviors in these studies were disregarded.25,26,30,37,42 One large study only measured 
opioid overuse.38 Underuse of medication ranged from 2% to 53% with a weighted mean of 
33%. Overuse ranged from 9 to 51% with a weighted mean of 33%, considering that the mean 
overuse rate was largely increased by a single large study on opioid overuse.38
Determinants
Nineteen studies were found to describe determinants of medication adherence of chronic 
non- malignant pain patients (Table 4). Factors most frequently mentioned as positive predic-
tors of non-adherence were higher dosing frequency, polypharmacy and low but also high pain 
intensity, followed by younger age, concerns about pain medication, and an unsatisfactory 
patient-caregiver relationship. Four studies made a clear distinction between determinants 
of medication underuse and –overuse.27,31,32,36 Underuse was associated positively with con-
cerns about side effects and addiction, and negatively with concerns about withdrawal and 
perceived need for analgesic medication.27,36 Active coping strategies and self-medication were 
also described to be positively associated with underuse as well.31,32 Overuse was associated 
positively with perceived need, pain intensity, opioid use, a history of drug abuse, smoking and 
a number of prescribed analgesics.27,31,32,38
We divided the factors predicting non-adherence into the five categories, as described by the 
World Health Organization: 
1. Socio-economic factors
Educational level was negatively associated with analgesic adherence in one study.33 Two stud-
ies did not find this association.32,39
2. Health care team and –system related factors
Difficulties in the therapeutic relationship, defined as mistrust in the doctor or discordance in 
communication and satisfaction, were negatively associated with adherence.24,27,36 Medication 
underuse was related to lack of information provided in the hospital.32
25
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Table 4. Determinants of medication adherence to pain medication in chronic pain patients
Author Year n Determinants of non-adherence Comments
berndt 1993 99 Polymedication, history of drug abuse
Mulleners 1998 29 Higher dosing frequency Article described 
medication prophylaxis 
instead of symptomatic 
treatment
De klerk 2002 127 Symptom modifying instead of disease controlling drug, higher dosing frequency, 
male sex
Better perceived health, coping patterns (avoidance related to lower compliance; 
expression of emotions
and passive reaction pattern related to better adherence)
Sewitch 2004 127 Unintentional: community subjects, lower disease activity, less use of instrumental 
coping, higher discordance on communication and satisfaction, not under 
rheumatologist’s care for more than a year.
Intentional: not under rheumatologist’s care <1 year, higher discordance on 
communication and satisfaction.
Overall: higher discordance on communication and satisfaction
Dobkin 2006 121 Lower aff ective pain ratings, higher psychological distress
McCracken 2006 220 Overall: lower pain intensity, mistrust in doctor, concern over addiction
Underuse: higher pain intensity, concern over side eff ects, less concerns over 
withdrawal, less perceived need
Overuse: higher pain intensity, perceived need, concern over scrutiny
Manchikanti 2005 200 Long acting opioids did not improve adherence
Ives 2006 196 Younger age, drug or DUI conviction, history of cocaine or alcohol abuse
Grattan 2012 1334 Misuse: depression
Opioid use for non-pain symptoms: male sex, lower daily dose, less education
Overuse: higher pain intensity
Overuse and aberrant behavior: younger age
Aberrant behavior: white race, less education, lower daily dose
barth 2014 307 Depression, high pain intensity, impaired psychological quality of life, alcohol use
Matteliano 2014 120 Age, pain level, sex, ethnicity, injury compensation did not predict aberrant drug 
taking behavior
Giannopoulos 2007 93 Patients on SSRIs were more compliant than patients on gabapentin
nicklas 2010 217 Adherence and Illness perceptions Questionnaire: perceptions of illness as chronic, 
uncontrollable and unremitting were more adherent.
Adherence and beliefs about medication: higher concerns were less adherent, higher 
necessity were more adherent
Age, pain level and educational level positive correlation with adherence
broekmans 32 2010 281 Underuse: younger age, more use of (non-prescribed) self-medication
Overuse: younger age, higher dose frequency, opioids prescribed, smoking
broekmans 33 2010 265 Underuse: higher number of prescribed analgesics, self-medication, lower pain 
intensity, active coping,
lack of information, side eff ects
Overuse: higher number of prescribed analgesics, smoking
Overall: higher number of prescribed analgesics, prescription of non-opioids
Rosser 2011 239 Overall: mistrust in doctor, concerns about side eff ects, less concern over withdrawal
Underuse: lower level of pain, mistrust in doctor, less concern over withdrawal
Overuse: perceived need, concerns about side eff ects
Stern 2011 1351 Higher pain intensity
Markotic 2013 100 Higher number of analgesics or other drugs, fear of addiction, side eff ects,
belief that sleepiness due to analgesics is bothersome, higher pain intensity. 
Timmerman 2013 96 Less knowledge of the prescription, higher age
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3. Condition related factors
Pain intensity was positively associated with adherence.27,29,33 More specifically, underuse was 
associated with lower pain intensity 32,36 and overuse with higher pain intensities.27,38,41 On 
the other hand, pain intensity was negatively associated with adherence in one study 40 and 
underuse was associated with higher pain intensity in two studies 27,34. One study reported no 
association between pain level and medication adherence.42
4. Therapy related factors
Polymedication and higher dosing frequency were negatively associated with adher-
ence.21-23,31,32,40 In two studies, compliance was associated with the type of medication pre-
scribed, i.e., patients on SSRI‟s were more compliant than patients on gabapentin.22,29 The use 
of opioids was described to correlate with overuse.31 Long acting opioids were described not to 
improve adherence, compared to short acting opioids.25
5. Patients related factors
Age was positively associated with analgesic adherence.26,31,33,38 One study described a negative 
association 39 and two studies reported no association between medication adherence and 
age.32,42 Perceptions of illness were reported to predict adherence, as patients that considered 
their illness as chronic, uncontrollable and unremitting were more adherent.22,33 Patients that 
used active coping strategies and self-medication to improve their symptoms were underus-
ing their analgesics more often.31,32 Knowledge of prescribed pain medication was positively 
related to adherence to this prescription.39 
Attitudes and concerns towards pain medication were reported to predict adherence.27,33,36,40 
Perceived need for pain medication was associated with overuse, less perceived need was 
associated with underuse.27,36 Concerns about addiction, adverse scrutiny and tolerance were 
positively associated with a general measure of non-adherence, whereas concerns about 
side effects and little concerns about withdrawal symptoms correlated with prescription 
underuse.27,36,40 Psychological distress positively predicted non-adherence in two studies.29,41 A 
history of drug abuse 21,26 as well as smoking 31,32 predicted overuse non-adherence. 
Quality assessment
Thirteen of the 25 selected studies were of high methodological quality (Table 5).21,22,25-27,31,32,34, 38-42 
Although 17 studies fulfilled 7 out of 11 methodological criteria, 4 of these studies did not 
meet 4 of the essential criteria. Twelve studies did not use a validated measure of medication 
adherence, mostly self-report. Validated measures included urine screening, Medication Event 
Monitoring System (MEMS), Current Opioid Misuse Measure (COMM) and both versions of the 
Morisky Medication Adherence Scale: 4 questions (MMAS-4) or 8 questions (MMAS-8).
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Confl icts of interest
Six studies reported funding by internal or external research grants.14,22,27,28,35,38 Confl icts of 
interest were declared in three reports.34,37,42 Stern and colleagues are employees of Grunenthal 
Pharma SA.34 Bronstein declared to be employee at the medical aff airs department of Ameritox, 
a company that provides urine drug tests.37 Mattelliano reported to be an educational speaker 
at Millenium laboratories, a company that provides urine drug tests. 
Table 5. Results of the quality appraisal with the quality assessment checklist.
References
Selection 
methods
Measurement of study 
variables
Sources of bias
Control of 
confounding
use of statistics Score
Question 1 2 3 4 5 6 7 8 9 10 11
Markotic y y y y y n y y y y y 10
barth y y y y y dk y y y y y 10
De klerk y n y y y y y y y y y 10
Grattan y y y n y y y y y y y 10
Stern y y y n y y y y y y y 10
broekmans (2) y y y n y y y y y y y 10
Ives y y y n y y n y y y y 10
broekmans (1) y y y n y y dk y y y y 9
Timmerman y y y n y y n y y y y 9
McCracken y y y n y n y y y y y 9
Sewitch y dk y y y n y y y y y 9
berndt y dk y y y y y y n n y 8
Manchikanti y y y y y y y y n n na 8
Rosser y n y y y n n y y y y 8
nicklas y n y n y n y y y y y 8
Dobkin y dk y y y n n y y y y 8
Mattelliano y na y y y y y n n y na 7
Giannopoulos y dk y n y y dk y n y na 6
Chang y dk y y y y n n n y na 6
Mulleners y dk y y y y dk n n y na 6
navato y y y y na y dk na na n na 5
bronstein n y y y na y y na na n na 5
Weinberger y n y n y y n y n n na 5
Lewis y n n n y dk n na na n na 2
Packard y dk n n n n y na na n na 2
Bold scores indicate high-quality studies. y, yes; n, no; na, not applicable; dk, don’t know.
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DISCuSSIOn
Non-adherence to prescribed analgesic therapy is common in patients with chronic non-
malignant pain, and might be one of the reasons that efficacy of medication in this population 
is limited.34 A causal relationship between medication adherence and medication efficacy, how-
ever, has never been established in chronic pain management. As chronic pain is a complex, 
multifactorial disease, it is difficult to prove the importance of medication adherence, as the 
effect of analgesic therapy is generally limited. 
Non-adherence to chronic disease treatment is generally associated with increased morbidity 
and mortality.3 It is not known if the same holds true for adherence to symptomatic analgesic 
treatment in patients with chronic pain. At least, assessment of medication adherence is im-
portant to evaluate the ability of prescribed medication to control pain. We reviewed literature 
for the prevalence and determinants of non-adherence. We did not pool the data of studies 
because of the large differences in study design, studied populations, definitions of adherence, 
and methods of adherence measurement. 
Prevalence
Pain medication non-adherence was common and generally more prevalent compared to 
non-adherence to other chronic disease treatments. In some chronic conditions, for example 
hypertension, non-adherence can be explained by the fact that there is no noticeable gain of 
medication. Although it seems obvious that ongoing pain and limitations motivates patients to 
take their medications correctly, adherence to symptomatic pain treatment has been described 
to be even worse than adherence to disease modifying drugs.22 
Besides differences in pain diagnoses, the wide range of non-adherence rates may be 
explained by differences in defining and operationalizing non-adherence across the studies: 
first, although some studies in chronic-pain populations define non-adherence as any report 
of a missed dose or deviation of the prescription, other studies use more liberal definitions of 
adherence. Nevertheless, even in comparable studies with respect to population and adher-
ence definition, large differences exist in the prevalence of non-adherence. Second, underuse 
and overuse non-adherence should be considered as two different entities with their own 
prevalence and determinants. However, most studies either focus on underuse or do not 
mention this distinction at all. Another explanation for the wide range of non-adherence rates 
may be that taking medication is in fact complex behavioral pattern, and whereas data on 
adherence are often reported as dichotomous variables (adherence vs. non-adherence), this 
might be an oversimplification of the subject.15 Moreover, adherence can change in time, as 
it is a dynamic process. ‘White coat adherence’ is a phenomenon that has to be accounted for 
when interpreting study results: patients may follow prescriptions better just before and after a 
follow-up visit.43 Finally, several methods were used to measure medication adherence. Subjec-
tive methods (self-report and a structured interview), using validated questionnaires or simple 
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questioning were most frequently used. They are easy to apply and inexpensive. Unfortunately, 
they tend to overestimate compliance.44 Objective methods are generally more reliable for 
monitoring adherence. A Medication Event Monitoring System (MEMS), an electronic pillbox 
which records pill box openings, is an example of objective adherence monitoring. Although 
it is used as an adherence monitor, patients are aware of being monitored, and MEMS may 
partly be considered as an adherence intervention. Urine analysis is widely used to monitor 
adherence, especially in patients on chronic opioid therapy. It is reliable to detect prescription 
drugs and illicit substances qualitatively. Quantitative measurements are less reliable because 
of inter-individual diff erences in metabolism.45 Therefore, patients overusing their medication, 
mostly opioid users, will not be identifi ed by urine testing alone. Other methods to measure 
compliance with treatment regimens are pill count, or calculation of the medication possession 
ratio (MPR), which requires a closed pharmacy system.15 Each method has its advantages and 
pitfalls. At this point, patient interview remains the most practical approach for clinicians, while 
a combination of adherence measures seems to be optimal for research purposes.46
Determinants
The choice for a specifi c therapeutic regimen might infl uence adherence behavior. Poly-medi-
cation and higher dosing frequency may negatively infl uence adherence, and a higher number 
of analgesics is associated with underuse of prescribed therapy.21-23,31,32,40 Therefore, it may be 
benefi cial to limit the number of analgesic prescriptions in patients at risk for non-adherence. 
However, although the eff ect of once day dosing schedules on adherence has been shown, the 
eff ect on outcome has not been established. Chronic pain patients that sense the eff ect of each 
individual dose might prefer more daily dosing as a way to keep control over their symptoms. 
The type of medication prescribed may play a role in the patterns of medication use. 
Overuse was more prevalent in, but not limited to, patients taking opioids. Grattan et al. 
described in their large study that half of the patients taking opioids were overusing their medi-
cations. Most important reasons for this are the strong and relatively fast mode of analgesic 
action of opioids (noticeable gain), and the existence of opioid dependency, abuse or addiction. 
In one study, patients with diabetic neuropathy were more adherent to antidepressant (SSRIs) 
than to anticonvulsant (gabapentin) therapy.29 Another study that was excluded for this review 
confi rmed these fi ndings. 47 This could possibly be explained by the fact that SSRIs are better 
tolerated and that they are dosed, unlike gabapentin, once a day. 
Unfortunately, most pain medications cause side eff ects. Surprisingly, the presence of side 
eff ects was related to non-adherence in only two studies.32,40 Most side eff ects occur at the 
beginning of the therapy, and unacceptable side eff ect will be followed by a dose reduction or 
change of therapy. Therefore, non-adherence due to side eff ects will be missed in a more stable 
treatment regimen in which patients were seen in most studies reviewed.
Beliefs about illness and beliefs about medication are important predictors of adherence be-
havior.27,33,36 Perceptions of illness as chronic, uncontrollable and unremitting were reported to 
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predict adherence positively.33 To increase the likelihood of adequate adherence it is important 
that perceptions of necessity of analgesic therapy outweigh specific concerns regarding the 
prescription.
The caregiver-patient relationship has been mentioned in three studies as an important 
determinant of non-adherence.24,27,36 The consultation itself plays an important role, as the 
relationship between physician and patient will be built here. Providing adequate information, 
shared decision making and proposing a treatment plan with feasible goals may ensure a 
positive patient-physician relationship without mistrust. Furthermore, attitudes and concerns 
towards illness and medication can be addressed in this consultation, and alternative treat-
ment options can be proposed.14, 27,36 Patients have to realize that they carry responsibility for 
the success of their treatment as well, and they should be actively involved and motivated.48
Adherence and treatment outcome
In chronic pain, there is no consensual standard for what constitutes adequate adherence. 
As it is symptomatic treatment, it might not be justified to label non-adherence as ‘incorrect’ 
behavior automatically. In some serious chronic conditions such as HIV-infection, strict adher-
ence is mandatory for positive treatment outcome. In chronic pain, some deviation from the 
prescription may be acceptable without serious consequences for treatment efficacy. In fact, 
as described above, a causal relationship between adherence and pain reduction has never 
been shown for chronic pain treatment until now. The relationship between adherence and 
outcome is even more complex, as ‘good outcome’ is not well defined. Some patients prefer 
other outcomes than pain reduction, e.g., the ability to drive a car or having no side effect of 
prescribed medications. 
Pain intensity has been associated with adherence in both directions. If there is little or no 
pain, patients may feel pain medication unnecessary. High pain levels may be interpreted as 
a higher need for pain medication, and may therefore lead to better adherence or even over-
use of pain medication. On the other hand, patients who do not use their medications may 
have higher pain intensities than patients that use their prescription correctly. Adherence to 
medication is also thought to improve outcome by mechanisms other than the actual effects 
of medication. In one study on B-blocker use, adherence to placebo was strongly associated 
with mortality.49 The authors concluded that, while probably not due to publication bias or 
simple confounding by healthy lifestyle factors, the underlying explanation for the association 
remained ‘a mystery’. Adherence itself might be seen as a measure of, or proxy for, other positive 
behavioural properties that are beneficial for people with HTN or pain. 
Predicting non-adherence in general practice
When considering prescription of pain medication, the risk of non-adherence should be con-
sidered. Several efforts have been made, especially in the field of opioid prescribing, to stratify 
patients into risk categories. Questionnaires as the Prescription Drug Use Questionnaire (PDUQ), 
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Diagnosis Intractability Risk and Effi  cacy Score (DIRE) and the Pain Medication Questionnaire 
(PMQ) have been developed to predict aberrant opioid taking behavior.12, 50-52 
Non-adherence to pain medication might be anticipated by identifying risk factors for non-
adherence as described above, including younger age, polymedication, negative attitudes or 
concerns towards the use of medication, psychological distress and a history of drug abuse. 
Patient at risk might benefi t adherence improving interventions or alternate therapy.
Interventions
Interventions that improved medication adherence are mostly described in other chronic con-
ditions: simplifi cation of the medication regimen, patient education, behavioral interventions 
(reminders, encouragement), SMS-reminders and eHealth-interventions.2,4-10 Interventions 
to improve non-intentional non-adherence, for example SMS reminders, may be more easily 
implemented than interventions for intentional non-adherence in a chronic pain population. 
Improvement of intentional non-adherence might need a more patient tailored intervention 
targeted at determinants of inadequate medication use. 
Regular follow-up and monitoring for adherence monitoring have been shown to improve 
medication-taking behavior in chronic opioid therapy.53,54 In the American literature, in which 
opioid abuse is predominantly described to be a serious and extensive national health problem, 
routine drug testing during opioid therapy is advocated.54,55 In chronic non-opioid pain therapy, 
only one intervention was studied without signifi cant eff ect on medication adherence.20 
Limitations
The results of this review were partly based on studies of limited methodological quality. 
However, half of the studies were of high quality, and results of low quality studies generally 
confi rmed fi ndings of high quality studies regarding non-adherence rates and determinants of 
non-adherence. The main limitation of this study is the heterogeneity of the studies reviewed 
with respect to defi nition of adherence, adherence measurement, study design and pain 
diagnoses. Focusing on a smaller subset of studies would have led to insuffi  cient data for an 
update on this subject. Furthermore, as our literature search was limited to two databases, and 
our search criteria did not include specifi c diagnoses, we might have missed relevant records 
in this review. Nevertheless, we assume to have provided a representative overview of current 
literature on the topic of pain medication adherence.
COnCLuSIOn
In conclusion, the number of publications on prevalence and determinants on medication non-
adherence in chronic non-malignant pain patients has increased in the last decade. Medication 
non-adherence in chronic pain patients is common, and factors predicting non-adherence 
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have been presented. Despite this, there is still no evidence for the importance of adherence on 
pain reduction. Future studies should investigate if, and to what extent, medication adherence 
is actually important for pain treatment outcome. The actual prescription of pain medication 
should be part of a larger treatment plan including non-adherence risk stratification, informa-
tion, shared decisions about treatment strategy and adequate follow-up including monitoring 
of medication use. Possibly, additional interventions as reminders, patient education or eHealth 
applications might play a role, but their role has to be evaluated in future studies. 
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AbSTRACT
background
Non-adherence to pharmacological therapy is a common and underexposed problem in 
chronic non-malignant pain patients. It may lead to treatment failure and increased health care 
costs. 
Methods
In this prospective observational study we analysed the association between knowledge and 
adherence in the chronic non-malignant pain population. We included 96 patients treated with 
a new pharmacological prescription. During the initial visit (T0) demographic variables, pain 
intensity, knowledge of the prescription (name, dose and frequency), self-reported adherence 
to the prescription and general knowledge of pharmacological pain therapy (according to the 
Pain Knowledge Questionnaire, Dutch Language Version (PKQ-DLV)) were recorded. During 
two follow-up visits (T1, T2), apart from demographics, these parameters were measured again.
Results
Adherence rates were 42%, 42% and 46% at T0, T1 and T2, respectively. 53%, 59% and 48% of 
patients had knowledge of their current prescription, and mean scores on the PKQ-DLV were 
56, 55 and 52 percent of the maximum scores, respectively at T0, T1 and T2. A multivariate 
binary logistic regression analysis resulted in a significant contribution of knowledge of the 
prescription and of age to the prediction of adherence.
Conclusions
Knowledge of the analgesic prescription is associated with adherence and significantly con-
tributes to the prediction of adherence to analgesic therapy. An interventional study is needed 
to determine whether increasing knowledge will improve medication adherence and therapy 
outcome in chronic non-malignant pain patients.
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InTRODuCTIOn
Chronic non-malignant pain is a common health problem that leads to disability as well as 
high medical and societal costs. Although over 60% of pain suff erers use medication to relieve 
their pain, this therapy is often not eff ective. Non-adherence to the prescription is reported to 
play a major role in the sub-optimal eff ect of chronic pharmacological therapy.1 The prevailing 
defi nition of adherence is ‘the extent to which a person’s behaviour (in terms of taking medica-
tion, following diets, or executing lifestyle changes) coincides with medical or health advice’.2 
Broekmans et al. reported that in patients with chronic non-malignant pain, non-adherence is 
common: 29.9% (range 2-53%) of the patients used less medication and 13.7% (range 3-21%) 
used more medication than prescribed.3 
Non-adherence to prescribed analgesics is an underexposed problem in chronic pain man-
agement. For other chronic conditions (e.g. HIV infection, asthma, diabetes and cardiovascular 
disease) much more is known about the prevalence and determinants of non-adherence and 
interventions to improve adherence.1,2,4 In general, poor adherence to medication accounts for 
a substantial worsening of disease, readmissions to the hospital, death, and increased health-
care costs.5 Recently, it has been shown that adherence to prescribed medication is negatively 
associated with pain intensity.6 However, it is still unknown whether a causal relationship exists 
between adherence and the outcome of chronic pain therapy. In some serious chronic condi-
tions such as HIV-infection, strict adherence is mandatory for positive treatment outcome.7 In 
chronic pain management, some deviation from the prescription may be acceptable without 
serious consequences for treatment effi  cacy. 
Knowledge of determinants of medication adherence contributes to the prediction and 
identifi cation of non-adherent behaviour in clinical practice. Furthermore, understanding why, 
when and which patients are non-adherent is essential for developing strategies to improve 
medication taking behaviour. Adherence research in chronic pain management has, due to 
increasing reports of prescription medication abuse, been primarily focused on identifi cation 
and prevention of opioid overuse and abuse.8,9 However, most deviations from physician in-
structions are omissions, i.e. underuse of medications.5 Determinants of medication underuse 
that are reported in chronic pain management include age, psychological distress, poor com-
munication with providers, lower aff ective pain ratings, poor clinical attendance 3, active coping 
strategies and use of self medication.10 Furthermore, patients’ concerns and beliefs about the 
prescribed therapy play an important role in their medication taking behaviour.11-13 
Knowledge of the disease or the prescribed therapy was found to be positively correlated 
to medication adherence in other conditions, and patient education was successfully used to 
improve adherence.14-17 The present study investigates the association between knowledge 
and adherence to a pharmacological prescription in patients with chronic non-malignant pain. 
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METhODS
Design
Our study was a prospective observational study. 
Patients
Included were consenting outpatients with chronic non-malignant pain persisting for at least 3 
months, who were treated with a new pharmacological pain prescription at the Center of Pain 
Medicine of the Erasmus Medical Center. Patients had to be aged ≥18 years and have adequate 
understanding of the Dutch language. Excluded from the study were patients receiving pain 
medication on an ‘as needed’ basis.
Measurements
Measurements were made during the first visit to our Center of Pain Medicine (T0), and during 
two consecutive follow-up visits after one (T1) and three months (T2), respectively. Patients 
underwent a structured interview by study personnel not involved in clinical care of the study 
participants. At T0 measurements included: demographic variables (age, gender, educational 
level); medical variables (location and duration of pain, mean pain intensity in the previous 
week using an 11-point numeric rating scale 18) and medication adherence: the prescribed pain 
therapy was compared with the anamnestic use of medication the day before measurement: 
‘which pain medication(s) did you use yesterday?’. Knowledge of the prescription was deter-
mined by asking for the name, dose and frequency of the therapy prescribed and comparing 
the result with the actual prescription as noted in the patient file. In addition, general knowl-
edge on the pharmacological pain therapy was evaluated using a Dutch language version of 
Ferrell’s Patient Pain Questionnaire.19 This questionnaire consists of eight statements that could 
be answered on a five point Likert-scale (strongly agree, agree, not agree/not disagree, dis-
agree, strongly disagree). For ease of interpretation, all item scores were linearly transformed to 
a 0-100 scale and a total score was computer for overall pain knowledge. This Pain Knowledge 
Questionnaire (PKQ-DLV) was translated backward and forward and pretested in a group of 
49 chronic cancer pain patients. It demonstrated acceptable levels of validity and reliability.20 
At T1 and T2, apart from demographics, location and duration of the pain, all the aforemen-
tioned parameters were measured again. Knowledge of the prescription and adherence to it 
were assessed using to the current pharmacological pain therapy.
Data analysis
Adherence to prescribed therapy was determined by recording adherence to: the drug, the 
dose of the drug, and the frequency of the prescribed dose regimen. Any deviation regarding 
the type, dose or frequency of medication in relation to the prescribed therapy was defined as 
non-adherence. Overall adherence was defined as adherence at T1 and T2 to all three aspects 
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mentioned above. Knowledge of the name, dose and frequency was recorded dichotomously 
and overall knowledge was defi ned as knowledge at T1 and T2 of all three aspects. T0 was left 
out of the analysis because knowledge measured at T0 concerned knowledge of the newly 
prescribed medication (and not knowledge of earlier prescribed therapy as at T1 and T2).
Item scores of the PKQ-DLV were linearly transformed to a 0-100 scale, after recoding fi ve 
items, and a total score was computed for general pain knowledge. 
Statistical analysis
Descriptive statistics were used to determine frequencies. Binary logistic regression analysis 
was used to evaluate the contribution of parameters to the prediction of adherence to the 
prescribed medication. To prevent overfi tting of the model, we performed univariate binary 
logistic regression analyses of demographic parameters (gender, age and education), overall 
knowledge of the prescription, general knowledge of pharmacological pain therapy at T0, and 
pain intensity in the previous week at T0. Only those parameters with a signifi cance level of p ≤ 
0.2 were entered into the fi nal multivariate stepwise binary logistic regression analysis (method 
Backward Wald) with a probability out of p=0.1. To prevent multicollinearity, pairwise correla-
tions between the parameters to be entered into the fi nal model were calculated. Of those with 
a bivariate correlation of ≥ 0.7 only the parameter with the highest univariate signifi cance level 
was entered into the fi nal model. Analyses were performed with the Statistical Package for the 
Social Sciences (SPSS), version 16.0.
RESuLTS
Demographics
Of the 112 patients initially included in the study, 17 
later declined to participate. 
At T0, T1 and T2 a total of 95, 88 and 79 patients, 
respectively, participated in the study. At T0 there 
were 30 (31.6%) male and 65 (68.4%) female partici-
pants with a mean age of 52.5 (SD 15.1) years; details 
of their educational level are given in Table 1. In the 
week prior to T0, mean pain intensity was 7.8 (SD 
1.5). At T0, 62 patients were unemployed (65.3%), 27 
of them (43.5%) due to functional disability.
Medication
Table 2 lists the analgesic therapy of patients before and after their fi rst visit to the Center of 
Pain Medicine. Of all patients, 25% did not use any medication at all before their initial visit. 
Table 1. Level of education at T0 according 
to the International Standard Classifi cation 
of Education (1997).
n (%)
None 2 (2.4)
Primary education 12 (14.5)
Lower secondary education 44 (53.0)
Upper secondary education 14 (16.8)
Tertiary education 11(13.3)
Total1 83 (100)
1 Data of 12 patients are missing.
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Co-analgesics (antidepressants and anticonvulsants) were prescribed more frequently at the 
Center than in earlier therapy, and therapy with sedatives and hypnotics was rarely prescribed.
Table 2. Analgesic therapy before and after the first visit to the Center of Pain medicine.
Medication before treatment 
(n (%))
Medication after treatment 
(n (%))
Step 1 WHO ladder 54 (57.4) 19 (20.2)
Step 2 WHO ladder 31 (33.0) 10 (10.6)
Step 3 WHO ladder 12 (12.8) 6 ( 6.4)
Anticonvulsants 15 (16.0) 24 (25.5)
Antidepressants 12 (12.8) 20 (21.3)
Anti-migraine medication 2 (2.1) 0
Hypnotics, sedatives, anxiolytic medication 18 (19.1) 1 ( 1.1)
Sympathicolytic medication 1 (1.1) 1 (1.1)
Muscle relaxants 3 (3.2) 0
Topical medication 1 (1.1) 0
Vasodilator therapy 1 (1.1) 2 (2.1)
Other 3 (3.2) 1 (1.1)
Unknown 4 (4.3) 28 (29.8)
No analgesic therapy 25 (26.6) 0
Total1 182 (193.6) 112 (119.1)
1Data of 1 patient are missing. Total score exceeds 100%, indicating that some patients used more than one 
analgesic drug.
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figure 1. Percentage of patients adherent to the drug, dose and frequency of the prescription, and the 
combination of these three aspects (overall adherence).
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Medication Adherence
Figure 1 shows the proportion of patients that were adherent to the prescribed pain therapy 
during the study period. Overall adherence to the prescription is 42, 42 and 46 percent at T0, T1 
and T2, respectively. Adherence to single aspects of the prescription was only slightly higher. 
There were no signifi cant diff erences between the diff erent aspects of adherence (adherence 
to drug, dose, frequency). There was no signifi cant diff erence between measurements at T0, T1 
and T2.
General knowledge of analgesic therapy
Table 3 presents data on general knowledge of pharmacological pain therapy. The lowest level 
of knowledge concerned the question ‘In analgesic therapy, it is important to use the lowest pos-
sible dose. Higher doses can then be reserved for more severe complaints’. The 
knowledge of the prescription
Figure 2 shows the proportion of participants that had knowledge of the specifi c aspects of 
their analgesic prescription. About 50% of the patients had overall knowledge on the diff erent 
aspects of their prescription during the study period. There were no signifi cant diff erences be-
tween the diff erent aspects of the prescription, or between the measurements at T0, T1 and T2.
Logistic regression analysis
The univariate binary logistic regression analyses revealed that only overall knowledge of the 
prescription (p=0.01), general knowledge of pharmacological pain therapy (p=0.05) and age 
(p=0.08) signifi cantly contributed to the prediction of adherence. 
Table 3. General knowledge on analgesic therapy according to the PKQ-DLV. Data are shown as mean 
scores (SD) on the eight questions on pain therapy. Higher scores indicate better pain knowledge.
T0 T1 T2
Pain can be treated eff ectively. 52.6 (30.4)a,b 60.8 (29.8) a 56.6 (31.4) b
Pain therapy should only be considered in case of severe pain. c 49.7 (39.0) 45.2 (41.3) 42.4 (35.9)
Most patients who use analgesic medication will develop some sort of addiction over time. c 43.2 (32.1) 37.2 (34.1) 39.2 (33.9)
In analgesic therapy it is important to use the lowest dose possible. Higher doses can then be 
reserved for more severe complaints. c
36.3 (41.9) a,b 27.3 (36.1) b 15.2 (26.4) a,b
It is advised to use analgesic therapy on a regular basis, instead of dosing on an ‘as needed’ 
basis.
80.3 (30.3) 79.3 (33.3) 78.5 (33.7)
There are other ways to treat pain besides analgesic medication. 66.6 (31.7) 71.0 (31.0) 70.6 (31.2)
Too many patients receive too much analgesic medication. c 40.8 (34.0) 43.2 (35.9) 41.8 (34.1)
I can easily change the prescribed analgesic regimen myself, without consulting my doctor. c 70.8 (38.2) 72.4 (35.0) 67.4 (38.3)
Total score 55.9 (14.4) a,b 54.8 (16.1) b 51.7 (14.2) a,b
a,b Signifi cant diff erence between groups are indicated by identical superscripts (p<0.05).
c Items were recoded
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Entering the above-mentioned parameters into the final multivariate binary logistic regres-
sion analysis resulted in a significant contribution of overall knowledge of the prescription and 
of age (Table 4). The sensitivity (71.4%), specificity (70.6%), and overall classification (70.8%) 
were high. A cut-off value of 0.24 was used. 
DISCuSSIOn 
Whether strict adherence is necessary to optimize outcome of pharmacological pain therapy, is 
unknown. In chronic pain, some deviation from the prescription may be acceptable. 
Nevertheless, as ‘drugs don’t work in patients who don’t take them’, awareness of medication-
taking behaviour is important when assessing the effect of prescribed therapy. In our chronic 
non-malignant pain sample, although mean pain intensities were high, adherence to prescribed 
analgesic therapy was low. During the 3-month study period ≤ 50 percent of the patients were 
adherent. Other studies measuring self reported adherence reported comparable high levels 
of non-adherence.21-23 The selected method of measuring adherence, i.e. self-report, can be 
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figure 2. Percentage of patients with knowledge on the different aspects and overall knowledge of the 
prescription.
Table 4. Results of the multivariate binary logistic regression analysis.
Included B (SE) [p-value]
95% CI for Odds Ratio
Lower Odds Ratio Upper
Constant 2.05 (1.68) [0.22]
Age - 0.08(0.04) [0.02] 0.86 0.92 0.99
Knowledge 2.09 (0.04) [0.02] 1.73 8.05 37.51 
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susceptible to misinterpretation as patients often overestimate their compliance to prescribed 
therapy.5 For this reason, it is unlikely that this method is responsible for the low levels of adher-
ence found in this and earlier studies.11,23 We defi ned every single deviation from the prescribed 
therapy as non-adherent behaviour. This strict defi nition, which is used in most adherence 
research in chronic pain, may partly account for the high levels of non-adherence found in this 
and other studies. Medication adherence is diffi  cult to operationalize, fi rstly because it is not a 
dichotomous variable but varies from 0 to more than 100% as people may overuse their medi-
cations.5 Secondly, it is a dynamic process, as it can change over time. We measured adherence 
the day before their visit, but this does not guarantee the same level of adherence on other 
days. ‘White coat adherence’ is a phenomenon that has to be accounted for when interpreting 
the results: patients may follow prescriptions better just before and after a follow-up visit.24
In the present study, about 50% of the patients had no knowledge of one or more aspects 
of the medical prescription. The regression analysis showed a signifi cant relationship between 
knowledge of and adherence to prescribed analgesic therapy. To depict the association be-
tween overall knowledge of the prescription and adherence, we performed a post-hoc univari-
ate analysis. Of those who were adherent, the proportion of patients with overall knowledge 
of the prescription (compared to those who had not) was found to diff er substantially; this dif-
ference was signifi cant (p <0.02, Fisher’s Exact test) (Fig. 3). Of those patients who did not know 
the name, dose or frequency of their analgesic regimen, 86.1% was non-adherent compared to 
54.2% of those who had this knowledge. In other words, patients who did not have knowledge 
of their prescription were signifi cantly less adherent to their therapy. 
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figure 3. Percentage of patients with and without knowledge of their prescription in relation to adherence.
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In this correlational study we cannot draw conclusions about the causality of the relationship 
between adherence and knowledge, but it seems plausible that knowledge of the prescription 
increases the chance of adherence to analgesic therapy. Asking for prescription details gives 
insight in the risk of non-adherence during clinical evaluation of a chronic pain patient. Even 
though it is possible to take medication correctly without knowing its’ exact name or dose, it 
is more likely if these items are known to the patient. Furthermore, it is almost impossible not 
knowing the dosing frequency and still use medication properly. This emphasizes that health-
care professionals should provide adequate information about the prescription. We defined 
knowledge of a prescription as knowledge of the name, dose and frequency. These basic items 
might not be the most important goals for an educational intervention. It seems unlikely that 
people who don’t know which medication they actually use will have sufficient knowledge 
of important properties of the prescribed therapy. Experiences in other chronic conditions 
demonstrate that education on prescribed medication alone might be ineffective.2,25 Commu-
nication should also address personal barriers and beliefs on pain medication, and education 
should focus on any specific concerns about prescribed medication.13 When pain treatment 
is started in an informed patient by shared decision after concerns have been addressed, the 
patient may be more likely to adhere to the therapy.12 
The results of the PKQ-DLV, in which only 56% of the maximum score was reached, suggest 
that basic knowledge on pharmacological pain therapy was low in this study population. The 
relationship between medication adherence and the results of the PKV-DLV was not significant 
in the final analysis. The PKV-DLV was designed and validated to test knowledge in cancer pa-
tients. Although non-malignant pain differs from cancer pain, it is assumed that the statements 
made on pain therapy can be used for non-malignant pain therapy as well. It has been used 
previously to test knowledge on non-malignant pain care in nurses 26, and the questionnaire 
appears suitable for use in a non-malignant pain population. Some statements, however, may 
not hold in this population, e.g. ‘pain can be treated effectively’. In nurses and in cancer patients, 
an educational intervention positively affected the total PKQ-DLV score.20,26
Our study demonstrated a negative association between age and adherence. This might be 
the result of polymedication being more prevalent in older adults. Polymedication has been 
shown to be an independent risk factor for nonadherence.27 Furthermore, decreased metabo-
lism and excretion due to organ failure can increase the risk of adverse effects of medication in 
elderly patients, resulting in premature cessation of prescribed therapy. However, other studies 
reported a positive association between age and pain medication adherence. 28,29 These studies 
had a different design and performed adherence measurements in a more stable treatment 
phase, after initial dose finding had been performed. Psychological factors and active coping 
strategies, that are more prevalent in younger patients, are reported to predict non-adherence 
and may play a more important role after the initial treatment phase. 10,30,31
In conclusion, the present study confirms that medication adherence of patients with chronic, 
non-malignant pain is low, with only about 50% complying with the prescribed therapy. In ad-
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dition, knowledge of the prescription is low as well. Importantly, our study showed that knowl-
edge of the prescription signifi cantly contributes to the prediction of the level of adherence 
to analgesic therapy. This fi nding could be used as a tool to defi ne the risk of non-adherence 
during evaluation of a chronic pain patient. Further study is needed to determine whether an 
educational intervention aimed at increasing knowledge of prescribed medication increases 
compliance with pain treatment and, most importantly, improves treatment outcome.
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AbSTRACT
Objective
Non-adherence to pain medication is common and may jeopardize the effect of prescribed 
therapy in chronic pain patients. We investigated the effect of medication-specific education 
on pain medication adherence. 
Methods
One hundred eligible chronic pain patients were randomized into a control or intervention 
group. They were assessed during an intake (T0) and two follow-up visits after 4 (T1) and 10 
weeks (T2). Immediately after T1, patients in the intervention group additionally watched a 
video and received written information about the medication prescribed. At T1 and T2, medica-
tion adherence according to self-report including the Morisky Medication Adherence Scale, 
prescription knowledge, pain intensity (NRS), concerns about medication and patient satisfac-
tion were recorded. 
Results
Experimental group (control versus intervention) did not significantly contribute to the predic-
tion of medication adherence at T2 ( p=0.38). The non-adherence rates were 31 and 43 percent 
at T1 and 53 and 49 percent at T2 in the control and intervention group, respectively. Changes 
in patients’ knowledge of the prescription were attributable to the intervention (p<0.01). No 
other significant differences were identified.
Conclusions
Medication-specific education did increase knowledge of the prescribed therapy but did not 
improve adherence or treatment outcome parameters. There was no association between 
medication adherence and pain treatment outcome. 
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InTRODuCTIOn
Chronic non-malignant pain is a common health problem that leads to disability as well as high 
medical and societal costs. Chronic pain of moderate to severe intensity occurs in 19% of adult 
Europeans.1 Although treatment requires a multidisciplinary approach, analgesic medication 
remains one of the cornerstones of the therapy. The response to drug treatment, which repre-
sents a complex interaction between analgesic medication and patient, is often poor and highly 
variable. There are several reasons for this variability. Age, gender, ethnicity and actual level of 
stress, mood or diseases may modify pain perception and pharmaco-genetic diff erences result 
in a variable response to pain medication.2 Non-adherence to pain medication is also thought 
to play a role in the sub-optimal eff ect of analgesic therapy. Non-adherence to analgesics is 
very common and it seems plausible that medication will not work if it is not used properly.3 
However, patterns of adherence behavior are complex, especially in chronic pain patients, and 
may include underuse, overuse and abuse of pain medications. To predict and anticipate non-
adherent behavior, risk factors for non-adherence should be addressed during consultation 
or, alternatively, by means of standardized checklists. Risk factors for non-adherence include 
younger age, complexity of the regimen, poly-medication, attitudes and concerns towards 
medication, low effi  cacy and side eff ects. Surprisingly, there are only few studies investigating 
interventions to improve medication adherence in the chronic pain patients.4,5 In a previous 
study, we presented an association between knowledge of the prescribed medication, and 
medication adherence.6 In this current study, we studied the eff ect of an educational interven-
tion on medication adherence. The intervention consisted of a medication specifi c information 
video combined with written information. We chose to investigate this intervention for three 
reasons: fi rst, we wanted to assess the eff ect of prescription knowledge improvement on medi-
cation adherence prospectively. Secondly, comparable medication videos, provided by phar-
maceutical companies, are used in clinical practice already, although their eff ects on adherence 
and outcome are actually unknown. Finally, a short video might be a realistic intervention for 
routine use in clinical practice, particularly under the current pall of cost-containment and staff  
reductions. Knowledge of prescribed therapy, attitudes and concerns about pain medication 
and pain treatment outcome were studied as secondary outcome parameters.
METhODS
Participants
After approval by the Institutional Medical Ethical Review Board, a single-center randomized 
clinical trial was carried out at the pain treatment center of a large general hospital in the 
Netherlands. Patients at this pain treatment center are most commonly referred by general 
practitioners, neurologists, neurosurgeons or orthopedic surgeons. This study was performed 
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from August 2012 until July 2013. Patients were invited to participate in the study if they had 
received a new analgesic prescription from their pain physician and if they did not meet any of 
the exclusion criteria. We excluded patients aged younger than 18 years, patients who did not 
have the ability to speak and read the Dutch language, and patients who received medication 
on an ‘as needed’ basis. All participants provided written informed consent. 
Study procedures
Patients, scheduled for an appointment at the pain treatment center, received written informa-
tion about the study together with other routine documentation. All consecutive patients who 
received a new analgesic prescription were invited to participate directly after their appoint-
ment at the hospital by physician assistants who were not directly involved in patient care. After 
written informed consent, study questionnaires were completed by participants during three 
subsequent visits at the pain treatment center: directly after inclusion and before initiation of 
the newly prescribed medication (T0), directly before the first (T1) and second (T2) follow-up 
visit after 4 and 10 weeks, respectively. After the visit at T1, patients were randomized into two 
groups using a computer-generated sequence with a single block with a ratio of 1:1. Patients 
were assigned to receive either standard care (control group) or standard care with additional 
medication-specific information after the first follow-up visit (T1)(intervention group). Both 
groups received their usual consultations, with a scheduled duration of ten minutes, with a 
pain physician during all visits (standard care). Communication during these consultations was 
not limited nor controlled. The additional information in the intervention group consisted of 
viewing a 5-minute video in the hospital directly after the consultation. This video contained 
recordings of a pain physician providing standardized information about the medication pre-
scribed: the name, frequently used dosing schedules, the type of medication (e.g. antidepres-
sant, anticonvulsant), mode and speed of action and common side effects were discussed and 
presented in summarizing slides. Videos of the following prescriptions were available: pregaba-
line, gabapentin, oxycodone, fentanyl, amitriptylin, duloxetine and NSAIDs. When applicable, 
basic differences between nociceptive and neuropathic pain were explained. At the end of the 
video, patients were encouraged to contact the pain center in case of questions or problems. 
Furthermore, written medication-specific information about these topics was provided in the 
intervention group. The pain physician was not aware of the allocation of the patient.
Outcome measures
At T0, the following variables were collected: age, gender, level of education, mean and worst 
pain intensity in the preceding week (using an 11-point numeric rating scale (NRS)) and number 
of medications. At T1 and T2, the following variables were collected: knowledge of name, dose, 
dosing frequency and type of the medication (multiple choice question, e.g. antidepressant 
drug, opioid medication etc.) prescribed. Diagnoses were collected from the medical files after 
the study.
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To increase reliability, we combined two separate self-report measures for medication ad-
herence. First, both underuse and overuse were measured by self-report by asking how often 
the participant missed a dose or took additional medication, using a 6-point scale (0=never 
to 5=every day). When patients reported underuse, the reason was recorded (forgot to take 
medication, adverse eff ects, drugs don’t work, pain under control, fear of addiction, other 
reason) to diff erentiate between intentional and unintentional nonadherence. The reason for 
overuse was recorded as well (accidentally, extreme pain, fear of withdrawal, other reason). 
Secondly, the 8-item Morisky Medication Adherence Scale (MMAS-8) consisting of 8 questions 
on medication adherence was used to measure pain medication underuse. It is a self-report 
measure originally designed to assess adherence to antihypertensive medications. It has good 
internal consistency (α=0.83) and concurrent and predictive validity.7 MMAS may function as 
a screening tool in outpatient settings in other patient groups. Mean and worst pain intensity, 
perceived level of improvement (7-point scale: 0= worse than ever to 6= complete pain relief ) 
and patient satisfaction (7 point scale: 0= absolutely dissatisfi ed to 6= absolutely satisfi ed) were 
recorded. Finally, the Pain Medication Adherence Questionnaire (PMAQ), a 47 -item question-
naire introduced by McCracken and colleagues, was completed.8 The PMAQ assesses 7 areas of 
patient concerns: addiction, perceived need, scrutiny, adverse side eff ects, tolerance, mistrust 
in the prescribing doctor, and withdrawal. Items are rated on a 6-point numerical scale (0=never 
true to 5=always true); nine items are reversed; and the subscales are mean scores of relevant 
items. Internal consistency reliability for these subscales is adequate based on Cronbach’s 
alpha values ranging from .77 to .85. Validity was demonstrated through signifi cant predicted 
relations between the subscales and measures of medication use, disability, and emotional 
distress.8 
Data analysis
Medication underuse was assessed by combining the results of both measurements of medi-
cation underuse described above. Underuse was defi ned as missing a dose once a week up 
to every day, regardless of pain intensity, and if they scored 2 or more positive questions on 
the MMAS. Medication overuse was defi ned as admitting to take any more medication than 
prescribed. General nonadherence was defi ned as presence of underuse and/or overuse of 
prescribed medication. 
Knowledge of the prescription was calculated by counting the correct answers on the indi-
vidual knowledge questions regarding name, dose, dosing frequency and type of medication, 
resulting in a minimum score of 0 and a maximum score of 4.
Statistical analysis
The a priori power analysis showed that a sample size of 80 was necessary to provide 80% 
power to detect a 10% change in adherence at α = .05; we planned to include patients until 96 
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patients were randomized to correct for missing data. Intention-to-treat analyses included all 
participants randomized. 
Descriptive statistics were used to determine the frequencies of the demographic variables 
and the outcome parameters and to describe measures of central tendency and dispersion de-
pendent on the shape of their distribution. The Kolmogorov-Smirnov test was used to analyze 
whether or not parameters were normally distributed.
Differences in proportions between the experimental groups at T0 were tested using the 
Fisher’s Exact Test in case of dichotomous parameters or in all other cases the Pearson Chi square 
Test. Differences in continuous variables were evaluated using the Independent-Samples Mann-
Whitney U test if the parameter was not normally distributed and the Independent-Samples T 
test if the parameter was normally distributed.
Binary logistic regression analysis was used to evaluate the contribution of the intervention to 
the prediction of adherence to the prescribed medication at T2 compared to the adherence at T1.
Differences in knowledge of and concerns towards the pain medication, pain intensities, 
perceived improvement, and patient’s satisfaction between experimental groups over time (T1 
to T2) were analyzed using multivariate repeated measures. Experimental Group and Time were 
the independent variables. 
For the non-normally distributed variables we still decided to use multivariate analysis of 
variance (MANOVA) test. Although MANOVA test requires that each dependent variable entered 
into the analysis be normally distributed it was still used because the Monte Carlo experiments 
have shown that for sample sizes of 3 or 5 it is still possible to analyze leptokurtic, rectangular, 
J-shaped, moderately, and markedly skewed distributions. These experiments demonstrated 
that the empirically determined rejection region of the F-distribution would be no larger than 
α = 0.08 when the usual 5% rejection is used.9
For all statistics, α was set at the traditional 0.05 level. All analyses were performed using IBM 
SPSS Statistics version 21. (SPSS, Inc, Chicago, IL).
RESuLTS
Study sample
In the period between August 2012 and July 2013, 123 patients were invited to participate, 
120 patients were included and 100 patients were randomized in this study (Figure 1). After 
informed consent, 2 patients withdrew their consent at T0. At T1, 18 additional patients were 
either lost in follow-up (6), received non-medication therapy (10) or withdrew their consent 
(2), leaving 100 patients to be randomized. At T2, 8 additional patients did not respond to the 
questionnaires due to loss in follow-up (4) or withdrawal of consent (4), leaving 92 patients that 
provided complete primary outcome data. Analyses were performed using data from these 92 
patients. The 47-item PMAQ was completed without omissions by 81 patients only. 
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figure 1. Study Flowchart 
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Demographics
Demographic variables of the included patients, i.e., level of education, diagnoses and number 
of other medications, are presented in Table 1. There were no significant differences between 
the control group and intervention group. Baseline characteristics in patients that did not finish 
the study did not differ from patients that did finish the study. Medications prescribed at T0 and 
T1 are presented in Table 2.
Table 1. Demographics
Control
 (n=45)
Intervention
 (n=47)
Age (SD) 60.2 (14.0) 58.5 (12.7) p=0.52
Gender (n(%)) male 17 (38) 24(51)
female 28 (62) 23(49) p=0.20
Mean Pain intensity mean (SD) 7.4 (1.4) 7.3 (1.6) p=0.84
Maximum Pain intensity mean (SD) 8.5 (1.0) 8.3 (1.3) p=0.40
Level of education (n(%)) Level 1. Primary education 1 (2) 4 (8)
Level 2. Lower secondary education 9 (20) 10 (21)
Level 3. Upper secondary education 9 (20) 13 (28)
Level 4. Post-secondary non-tertiary education 18 (40) 14 (30)
Level 5-6. Tertiary education 8 (18) 6 (13) p=0.28
Diagnosis (n(%)) Low back pain 11(25) 17 (37)
Neuropathic pain 17 (39) 16 (34)
Spinal canal stenosis 2 (4) 4 (9)
Neck pain 1 (2) 2 (4)
Arthritis 1 (2) 2 (4)
Atypical thoracic pain 0 (0) 1 (2)
CRPS type 1 1 (2) 0 (0)
Failed back surgery syndrome 5 (11) 2 (4)
Fibromyalgia 3 (7) 2 (4)
Frozen shoulder 2 (4) 0 (0)
Ischemic pain 1 (2) 1 (2)
Whiplash associated disorder 1 (2) 0 (0) p=0.61
Medication Adherence
The rates of non-adherence are presented in Table 3. The study allocation did not contribute to 
the prediction of non-adherence. Of the patients who reported underuse at T1, 39% of them 
did so intentionally; the others simply forgot to take their medication. At T2, 38% of the self-
reported under-users did so intentionally. All patients that admitted medication overuse were 
intentional over-users. 
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Table 2. Prescribed medication during visits at T0 and T1. IR=immediate release; LA=long-acting; 
CR=continued release.
T0 T1
Control
n (%)
Intervention
n(%)
Control
n(%)
Intervention
n(%)
Non-opioids
NSAIDs 3 (7) 4 (8) 5 (11) 3 (6)
Anti-convulsants 14 (31) 14 (30) 13 (29) 14 (30)
Anti-depressants 5 (11) 7 (15) 6 (13) 6 (13)
Anti-convulsants & anti-depressants 5 (11) 3 (6) 4 (9) 4 (9)
Opioids
IR-opioids (tramadol, codeine) 5 (11) 5 (11) 3 (7) 2 (4)
LA-/ CR-opioids (oxycontin, fentanyl) 11 (25) 10 (22) 9 (20) 12 (25)
Opioids and non-opioids
LA-/ CR-opioids & anticonvulsants 0 4 (8) 3 (7) 4 (9)
LA-/ CR-opioids & antidepressants 1 (2) 0 0 1 (2)
IR-opioids & anticonvulsants 1 (2) 0 2 (4) 1 (2)
Total 45 (100) 47 (100) 45 (100) 47 (100)
Table 3. General non-adherence, underuse and overuse at T1 and T2. 
Control Intervention binary logistic regression
Non-adherence n(%) T1 14/45 (31) 20/47 (43)
T2 24/45 (53) 23/47 (49) p=0.42
Underuse n(%) T1 11/45 (24) 15/47 (32)
T2 19/45 (42) 20/47 (43) p=0.75
Overuse n(%) T1 5/45 (11) 7/47 (15)
T2 7/45 (16) 8/47 (17) p=0.96
The rates of non-adherence, underuse and overuse did not diff er signifi cantly between non-
opioid users and opioid users in a secondary analysis at T2 (Table 4) . Furthermore, patterns of 
non-adherence did not diff er signifi cantly between direct-acting pain medication and slow-
onset neuropathic pain medication (anti-convulsants and anti-depressants).
knowledge 
Knowledge scores at T1 and T2 are presented in Table 5. No signifi cant eff ect of Group was 
found. Overall the knowledge between T1 and T2 improved signifi cantly (Time), (p <0.01). In 
addition, in the intervention group the knowledge of the prescription was signifi cantly im-
proved compared to the control group (Time*Group), (p<=0.01).
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Table 4 . Type of medication and frequency of non-adherence at T2. 
Opioids non-opioids p
Non-adherence n (%) 18 (47) 29 (54) 0.67
Underuse n (%) 12 (32) 27 (50) 0.09
Overuse n (%) 9 (24) 6 (11) 0.15
Anti-convulsants & anti-depressants Direct-acting pain medication
Non-adherence n (%) 27 (51) 20 (51) 1.0
Underuse n (%) 25 (47) 14 (36) 0.30
Overuse n (%) 6 (24) 9 (23) 0.16
Table 5. Results of the MANOVA analyses on knowledge and treatment outcome parameters. * p < 0.05; ** 
p < 0.01.
Outcome parameter 
Control 
mean (SD)
Intervention
mean (SD)
Time Group Time * Group
Knowledge (0-4)
T1 
T2
3.1 (1.3)
3.1 (0.9)
2.6 (1.2)
3.3 (1.0)
F(1,89)=7.0 ** F(1,89)=0.61 F(1,89)=7.0** 
Mean pain intensity (NRS)
T1
T2
6.3 (1.9)
6.1 (1.8)
6.3 (2.0) 
5.4 (2.2)
F(1,90)=7.26 ** F(1,90)=1.11 F(1,90)=3.29 
Maximum pain intensity (NRS)
T1 
T2
7.5 (1.8)
7.5 (1.5)
7.2 (2.0) 
6.5 (2.4)
F(1,90)=1.9 F(1,90)=4.1 * F(1,90)=2.50 
Perceived improvement (0-5)
T1 
T2
3.5 (1.1)
3.6 (0.9)
3.6 (0.9) 
3.7 (0.9)
F(1,90)=0.53 F(1,90)=0.41 F(1,90)=0.03 
Patient satisfaction (0-5)
T1 
T2
3.8 (1.4)
4.3 (1.4)
4.0 (1.2) 
4.3 (1.3)
F(1,90)=4.6 * F(1,90)=0.23 F(1,90)=0.51 
Treatment outcome
Treatment outcome measurements are presented in Table 5. There was no significant Group 
effect on mean pain intensity, but mean pain intensity in both study groups improved between 
T1 an T2 (Time; p=0.008; table 3). However, there were no significant differences in mean pain 
intensities attributable to treatment allocation (Time*Group; p=0.07). From T1 to T2, maximum 
pain intensities were significantly higher in the control group (Group; p<0.05). Time effect on 
maximum pain intensity was not significant. Differences were not attributable to allocation 
(Time*Group; p=0.12). Overall, the mean and maximum pain intensity between T0 and T2 
improved (Time; p<0.001 and p< 0.001, respectively; data not shown). 
Group effect was not significant for patient satisfaction. Whereas Time factor resulted in 
improved satisfaction in both groups (p<0.05), Time*Group interaction was not significant.
Concerns towards pain medication
Mean scores on the seven subscales of the PMAQ are presented in Table 6. Complete data were 
available for 42 patients in the control group and 39 patients in the intervention group. The 
factor Group, neither Time nor Time * Group yielded a significant effect. 
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Table 6. Concerns about medication according to the PMAQ (0=never true to 5=always true) and results of 
the MANOVA analysis. No signifi cant diff erences were found.
Concerns 
Control
mean (SD)
Intervention
mean (SD)
Time Group Time * Group
 Addiction
T1
T2
2.0 (1.1)
2.2 (1.3)
1.9 (1.0)
1.7 (0.7)
F(1,79)=0.001 F(1,79)=1.5 F(1,79)=3.0 
 Percieved need
T1
T2
3.4 (0.6)
3.3 (0.8)
3.3 (0.6)
3.2 (0.7)
F(1,79)=3.0 F(1,79)=0.22 F(1,79)=0.005 
 Scrutiny
T1
T2
1.5 (0.6)
1.6 (0.6)
1.5 (0.6)
1.5 (0.7)
F(1,79)=0.76 F(1,79)=0 F(1,79)=0.021
 Side eff ects
T1
T2
2.6 (1.1)
2.9 (1.2)
2.5 (0.9)
2.6 (1.0)
F(1,79)=1.5 F(1,79)=0.58 F(1,79)=0.58
 Tolerance
T1
T2
2.6 (0.9)
2.8 (0.9)
2.6 (0.8)
2.5 (0.8)
F(1,79)=0.17 F(1,79)=0.9 F(1,79)=1.6
 Mistrust
T1
T2
1.7 (0.7)
1.8 (0.6)
1.9 (0.8)
1.7 (0.8)
F(1,79)=0.21 F(1,79)=0.54 F(1,79)=3.4 
 Withdrawal
T1
T2
2.3 (1.1)
2.4 (1.5)
2.2 (0.8)
2.4 (0.9)
F(1,79)=3.9 F(1,79)=0.01 F(1,79)= 1.3 
DISCuSSIOn AnD COnCLuSIOn
Discussion
An educational intervention by means of a DVD presentation combined with written infor-
mation about the prescribed medication did not result in improved medication adherence 
compared to standard care in pain patients treated with new pain medication. It did, however, 
result in better knowledge of the prescribed therapy compared to the control group. Although 
a favorable trend towards an eff ect on mean pain intensity was found, treatment outcome 
variables and attitudes towards pain medication were not signifi cantly altered by standardized 
medication-specifi c education compared to standard care. 
Although knowledge has been associated with adherence, health belief models provide an 
explanation for the non-signifi cant results of the study. As demonstrated by the information-
motivation-behavioral skills (IMB) model of Fisher and Fisher, information is a prerequisite for 
changing non-adherence behavior, but in itself insuffi  cient to create this change.10 Motivation 
and behavioral skills are critical determinants and are independent predictors of behavior 
change as well (Figure 2). Low motivation decreases the likelihood of adherence, even in a 
highly informed patient. A single educational intervention may not be able to improve motiva-
tion or behavioral skills, and for this reason it fails to produce signifi cant changes in adherence 
behavior in this study. 
In order to be eff ective in improving medication adherence, some important aspects of the 
educational program might be restructured. First, the contents of the videos themselves should 
be reconsidered. Instead of limiting the information to details about prescribed medication, 
education outcomes might improve by providing additional information about chronic pain as 
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a disease, including treatment options, thereby placing prescribed medication into the context 
of a structured treatment approach. Furthermore, emphasizing the importance of medication 
adherence and providing practical tools to prevent non-intentional adherence may further 
improve the effect of the video on medication adherence. Secondly, the information provided 
might be more effective when it is offered in a patient-tailored manner by addressing individual 
needs and concerns of patients and their prejudices about pain medication.11-15 This could be 
achieved by tailored discussions with health care providers. Thirdly, repeated educational 
counselling including assessment of adherence behavior, ideally embedded in routine care, is 
probably more effective that a single educational intervention.12,13 Alternatively, this could be 
achieved by planned telephone coaching, patient-tailored eHealth or mHealth applications.14-16 
Finally, education should ideally be part of a larger self-management program containing 
behavioral and motivational support to create lasting behavioral changes and improvement of 
self-efficacy. However, these programs are complex and labor-intensive, making it difficult to 
see how they could be carried out in a non-research setting.17 Tailored internet-based support 
has shown promising results and might be a realistic way to provide long-term monitoring 
capabilities and patient support.18
As described in most studies, medication adherence was, again, disappointing.3 At the end of 
the study, half of the patients were non-adherent, regardless of their study allocation. Underuse 
was more common than overuse in both opioid and non-opioid users, as was described in earlier 
studies.11,19 The type of medication did not predict the direction of non-adherence. Although 
a trend towards less underuse in opioid users compared to non-opioid users at T2 was found, 
differences were not significant. To increase the reliability of the results, we used a combination 
of two self-report measures to assess adherence.20 Simply asking patients whether they used 
their medication or not resulted in higher adherence scores than use of the Morisky adherence 
scale. Nevertheless, the scores of both measurements had a common variance of .25 (p<0.001). 
In our previous study, we found a positive association between knowledge and medication 
adherence.6 We did not find this in the current study in a post hoc bivariate analysis (Pearson 
 
 
 
Health behavior 
motivation 
Health behavior 
information 
Health behavior 
skills 
Health behavior  
figure 2. Information-motivation-behavioural skills (IMB) model. Note. Reprinted from Fisher, W. A., Fisher, J. 
D. and Harman, J. (2003) The Information-Motivation-Behavioral Skills Model: A General Social Psychological 
Approach to Understanding and Promoting Health Behavior, in Social Psychological Foundations of Health 
and Illness (eds J. Suls and K. A. Wallston), Blackwell Publishing Ltd, Malden, MA. Copyright 2009 Wiley-
Blackwell. Reprinted with permission.
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correlation coeffi  cient (T2) -0.117; p=0.27). This may be explained by methodological diff er-
ences between both studies. Medication adherence was defi ned diff erently in this study, and 
instead of asking one question about medication use on the previous day we assessed adher-
ence in a longer time frame using a combination of methods. Furthermore, the previous study 
was performed in a University hospital. Our second study took place in a large general hospital. 
Standard care and the patient population might have been diff erent.
During this study, there was a signifi cant reduction of mean and maximum pain intensities, 
which might be caused by the newly prescribed medication. The overall improvement of pain 
intensities, however, was modest. We did not fi nd a correlation between medication adherence 
and mean pain intensity improvement or patient satisfaction (post-hoc bivariate correlation 
analysis, correlation coeffi  cient (T2) -0.009; p=0.931 and 0.157; p=0.136, respectively). Although 
some studies describe an association, a causal relationship between medication adherence and 
treatment outcome has never been demonstrated in chronic pain.21 Chronic pain is a complex 
disease, and therapy outcome is determined by multiple factors as diagnosis, psychological 
and socio-economic factors. The eff ect of medication is often limited, thereby automatically 
limiting the negative eff ect of non-adherence to this therapy on pain treatment outcome. 
Besides, patients may be satisfi ed with less than perfect analgesia and may prioritize other 
outcomes.22 Patients may think they are doing the right thing when they don’t take their medi-
cations, especially if symptoms are acceptable. It may be reasonable to study the relationship 
between medication adherence and treatment outcome in chronic pain before investigating 
further interventions focused on improving medication adherence. 
A limitation of this study might be the high number of patients who did not complete one or 
more questionnaires. Reasons were that they either were lost in follow-up, refused to repeat-
edly answer questionnaires or that a diff erent treatment without pain medication was initiated 
during the study. Although no signifi cant demographical diff erences were found between 
patients that did or did not fi nish the study, non-adherence levels may be diff erent in patients 
who do not keep hospital appointments or study agreements. Another limitation is the use of 
self-report measurements of adherence instead of more objective methods as urine analysis 
or electronic pill bottles. Although self-report is more easily used in clinical studies and daily 
practice, it is susceptible to overestimation of adherence. A fi nal important consideration in this 
study is that medication adherence, although presented as a dichotomous variable, is actually 
a complex behavioral pattern. It ranges from complete non-compliance to strict adherence to 
prescribed therapy, and it is dynamic and can change from day to day.
Do we have to provide medication-specifi c information on video to our patients? Patients 
should receive adequate information to make the best decisions for themselves about their 
own health and healthcare. An educational video may increase basic knowledge of the pre-
scription, and it can be used as an additional and inexpensive tool to explain the described 
therapy to pain patients and answer frequently asked questions. Nevertheless, it might not 
largely aff ect outcome.
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Conclusion
In conclusion, a medication specific educational intervention did not result in better medication 
adherence or improved treatment outcome compared to standard care, nor did it significantly 
alter patients concerns about medication. It did improve knowledge of the prescribed therapy. 
Moreover, there was no association between medication adherence and treatment outcome. 
Future studies should focus on the effects and cost-effectiveness of patient-tailored adherence 
interventions, motivational interviewing and behavioral support on pain medication use. More 
importantly, they should investigate the importance of strict medication adherence on pain 
therapy outcome. 
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AbSTRACT
Introduction 
Non-adherence to pain medication is common and may lead to poorer treatment outcomes. It 
is unknown which follow-up strategies could optimize medication adherence and pain treat-
ment effects. 
Aim
The objective of this randomized controlled clinical study was to compare the effect of three 
different follow-up strategies on medication adherence, therapy outcome and health care 
consumption in chronic non-malignant pain patients.
Methods
Three follow-up strategies were compared: (1) standard care, (2) intensive hospital-initiated fol-
low up, in which patients were contacted every two weeks, and (3) intensive patient-initiated 
follow-up, in which patients received standard care and additional follow-up on their demand. 
Primary outcome measure was medication adherence. Secondary outcome measures were 
pain intensity, patients satisfaction and number of patient contacts. 
Results
The level of medication adherence did not differ between the three offered follow-up strate-
gies. Furthermore, changes in pain intensities, patient satisfaction regarding medication, the 
care provided or the effect of pain treatment did not differ between the follow-up strategies. 
Compared to standard care, patient satisfaction regarding the provision of information was 
higher in the two other groups. The number of unplanned patient contacts did not differ 
between the study groups.
Conclusion
There was no difference in medication adherence between standard follow-up, intensified 
hospital-initiated follow-up or patient initiated follow-up in chronic pain patients. Except 
for the satisfaction regarding the information provided, treatment outcomes did not differ 
between these follow-up strategies as well. Patient initiated follow-up might be an acceptable 
and cost-effective alternative for long-term follow-up of chronic non-malignant pain patients.
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InTRODuCTIOn
Chronic pain has been reported by about one in fi ve adults throughout the world.1 Pharmaco-
therapy is an important component of pain therapy. Pain-relievers top the list of therapeutic 
drugs prescribed during visits to physician offi  ces and emergency rooms.2 It is well recognized 
that pain perception as well as pain relief after analgesic therapy display large interindividual 
variability.3 Age, gender, ethnicity and actual level of stress, mood or diseases may modify 
individual pain perception and responses to drug treatment.3 Furthermore, pharmacogenetic 
diff erences may lead to pharmacokinetic and –dynamic diff erences.4 Any of these factors may 
play a role in the (sub-optimal) eff ect of an analgesic treatment. 
Another important reason for sub-optimal treatment response might be that up to 40% of 
chronic pain patients do not use their medication as prescribed.5 Although the consequences 
of poor medication adherence in chronic pain patients are less clear than in other chronic 
conditions, it seems plausible that it leads to a reduced clinical benefi t, increased burden of 
side eff ects, medication wastage and increased healthcare costs as well.6 Furthermore, when 
physicians are unaware of patients’ non-adherence to their prescribed medications, treatment 
eff ect could be misinterpreted leading to unnecessary therapy changes.
Factors that have been found to be negatively associated with pain medication adherence 
are younger age, polypharmacy, poor quality of the doctor-patient relationship, concerns to-
wards pain medication and little knowledge of medication prescribed.5,7 Until now, knowledge 
of these factors has not been used to develop eff ective interventions to improve pain medi-
cation adherence. In other chronic conditions, successful interventions aimed at enhancing 
medication adherence have been reported and shown to be complex, and mostly consisted 
of frequent patient tailored counselling and education, and ongoing support from health care 
professionals.8 
In chronic pain management, it is unknown which follow-up strategy is eff ective in fostering 
adequate medication adherence. Although traditional patterns of patient follow-up vary, most 
patients initially visit their physician every six to twelve weeks, until the course of the condi-
tion has been established. A more intensive, hospital-initiated, follow-up strategy with more 
frequent evaluations of the eff ect of prescribed medication, tailored discussion of concerns, 
and ongoing reassurance might improve medication adherence and therapy outcome.8 How-
ever, this could well lead to overbooked outpatients services on the one hand, and increased 
number of unnecessary visits on the other. 
Patient initiated follow-up is another upcoming model of care which has been investigated in 
other chronic conditions as infl ammatory bowel disease, rheumatology and breast cancer. The 
aim of patient-initiated follow-up is to be responsive to the patient need.9-11 The patient decides if 
and when to consult a specialist, which may reduce unnecessary appointments. Patient-initiated 
follow-up might lead to a shift of medical utilities to patients who actually need these facilities. 
Furthermore, if the patient is empowered to initiate a specialist review, feelings of enhanced 
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self-efficacy and control may grow and consequently lead to improvement of clinical and 
psychological outcome. Up to now, patient-initiated care studies have shown promising results 
regarding patient satisfaction and health care efficiency. When combined with low-frequent 
planned consultation, the risk of harm is reported to be low.9-11 However, routine monitoring of 
medication adherence is difficult when medical care is delivered on demand. Therefore, the effect 
of patient-initiated follow-up on medication adherence is difficult to determine.
The objective of this randomized controlled clinical study was to compare the effect of three 
different follow-up strategies on medication adherence, therapy outcome and health care 
consumption, after a new prescription of analgesics in chronic non-malignant pain patients.
METhODS
After approval by the medical ethics committee, this randomized controlled clinical trial was 
performed at the pain treatment center of a large general hospital in the Netherlands. Patients 
at this treatment center are commonly referred by general practitioners, neurologists, neurosur-
geons, orthopaedic surgeons or plastic surgeons. All patients with non-malignant pain existing 
longer than 3 months who received a new analgesic prescription or who received additional 
pain medication to an existing treatment regimen, were invited to participate. Participants 
had to be able to complete electronic questionnaires in the Dutch language. Patients receiv-
ing medication on an ‘as needed’ basis and patients younger than 18 years were excluded. All 
participants provided written informed consent.
Procedures
All eligible patients received information about this study. As a part of standard care, a follow-up 
visit after 6 weeks was planned. After receipt of informed consent an email was sent containing 
a link to the web-based baseline questionnaire. After two weeks and after eleven weeks, the first 
and second follow-up questionnaires were sent. These follow-up questionnaires were identical.
After receipt of the first follow-up questionnaire, patients were randomized to one of the 
three study groups: (1) standard follow-up, which consisted of follow-up visits after 6 and 
12 weeks; (2) intensified hospital-initiated follow-up, which consisted of standard follow-up 
and additional scheduled counselling by a specialized nurse after 3, 5, 8 and 10 weeks; or (3) 
patient-initiated follow-up, which consisted of standard follow-up and additional counsel-
ling at patients’ request. Patients in the patient-initiated follow-up group were contacted by 
a specialized nurse as soon as possible, at least within 48 hours upon request for additional 
evaluation. For allocation of the participants, a computer-generated list of random numbers 
was used with a single block of 120 patients and 1:1:1 allocation ratio. Independent nurses of 
the pain treatment center allocated participants to one of the three study arms, and arranged 
additional contacts if needed according to the study allocation. 
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Outcome measures
Baseline data collected were: age, sex, level of education, mean and maximal pain intensity 
in the past week (using an 11-point numeric rating scale (NRS)), duration of symptoms and 
number of diff erent medications. 
Primary outcome measure was medication adherence measured 2 and 11 weeks after initia-
tion of a new prescription. Adherence was measured by asking two questions. One question 
measured underuse of pain medication: ‘You received a prescription for pain medication from 
your doctor. How often do you, intentionally or unintentionally, miss or skip a dose? ’. The sec-
ond question measured overuse of pain medication: ‘How often do you take more medication 
than prescribed? Answers were given on a 6 point scale (0=never, 1=seldom, 2= once a month, 
3=once a week, 4 more than once a week, not every day, 5=every day). 
Mean and maximal pain intensity in the previous week (NRS) were registered as secondary 
outcome measures at baseline, and after 2 and 11 weeks. After 2 and 11 weeks, satisfaction with 
treatment of pain was assessed using the Dutch translation of the Pain Treatment Satisfaction 
Scale (PTSS), generously provided by MAPI Research Trust, Lyon, France. The PTSS is a valid com-
prehensive instrument, consisting of seven independent modules and seven stand-alone ques-
tions, that has demonstrated satisfactory psychometric quality.12 The following items were used: 
(1) module ‘satisfaction with information about pain and its treatment’ (5 questions, e.g. how 
much information would you have liked to have about your illness or injury?)
(2) module ‘satisfaction with medical care’ (5 statements, e.g. it is easy to ask the medical staff  
questions) 
(3) module ‘Satisfaction with the eff ects of current pain medication’ (8 statements, e.g. my pain 
medication helps me have a better outlook on life)
(4) module ‘side eff ects of medication’ (identifi cation of side eff ects)
(5) module ‘satisfaction with current medication and care’ (9 statements, e.g. are you satisfi ed 
about the amount of time the doctors devoted to you during the visits? Are you satisfi ed 
about the amount of medication you take?)
(6) overall patient satisfaction (3 stand-alone questions, e.g. would you like to continue your 
current pain medication?). 
Furthermore, the names of the medications used were registered after 2 and 11 weeks. Follow-
ing the fi nal study visit after 12 weeks, the numbers of planned and unplanned contacts were 
registered.
Data analysis
Underuse was defi ned as missing a dose every week up to every day. Overuse was defi ned 
as taking additional medication every week up to every day. Non-adherence was defi ned as 
underuse and/or overuse of pain medication.
The subscales of the PTSS were scored as follows: Satisfaction with information about pain 
and its treatment: mean score of fi ve items (individual scores ranging from 1 (I would have 
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liked much more information), 3 (the information was right for me) to 5 (I would have liked 
no information)) were categorized into 3 groups (0<3 = would have preferred more informa-
tion; 3 = right amount of information; >3 = would have preferred less information); Satisfaction 
with medical care: mean score of five items, ranging from 1 (very positive) to 5 (very negative). 
Satisfaction with the effects of current pain medication: mean score of eight items, ranging from 
1 (very positive) to 5 (very negative). Satisfaction with current medication and care mean score 
of nine items, ranging from 1 (very satisfied) to 5 (very dissatisfied). The remaining questions 
were stand-alone questions analysed as such, all scored a 1 (very positive) to 5 (very negative). 
Statistical analysis
Regarding the absence of previous comparable studies, we chose to use a statistical detectable 
and clinically relevant within/between interaction effect size (f(V)) of 0,3 on medication adher-
ence, with a power (1-β) of 0,8, allocation ratio of 1:1:1 and a two-sided significance level of 0.05. 
The a priori sample size requires 37 patients per study arm. To correct for possible data loss, we 
planned to include 120 patients into the study.
Descriptive statistics were used to determine the frequencies of the demographic variables 
and the outcome parameters and to describe measures of central tendency and dispersion de-
pendent on the shape of their distribution. The shape of the distribution was analysed by using 
the Kolmogorov-Smirnov test. Differences in proportions between the experimental groups 
at baseline were tested using the Pearson Chi square Test. Differences in continuous variables 
were evaluated using the Independent- Samples Kruskal-Wallis Test if the parameter was not 
normally distributed and the One Way ANOVA if the parameter was normally distributed.
Binary logistic regression analysis was used to evaluate the contribution of the follow-up 
strategy to the prediction of adherence to the prescribed medication at 11 weeks using experi-
mental group and adherence at 2 weeks as a covariate.
Differences in pain intensities, PTSS-items and number of contacts between experimental 
groups over time (week 2 to 11) were analysed by means of MANOVA for repeated measures. 
Experimental group and time were the independent variables.
For the non-normal distributed variables we still decided to use multivariate analysis of vari-
ance (MANOVA)test. Although MANOVA test requires that each dependent variable entered 
into the analysis be normally distributed it was still used because the Monte Carlo experiments 
have shown that for sample sizes of 3 or 5 it is still possible to analyse leptokurtic, rectangular, 
J-shaped, moderately, and markedly skewed distributions. These experiments demonstrated 
that the empirically determined rejection region of the F-distribution would be no larger than 
α = 0.08 when the usual 5% rejection is used.13 The results are therefore presented as mean ± 
standard deviation (SD).
For all statistics, alpha was set at the traditional 0.05 level. All analyses were performed using 
IBM SPSS Statistics version 24 (SPSS, Inc, Chicago, IL).
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RESuLTS
From November 2014 up to November 2016, 152 patients consented to participate. One hundred-
and-thirty-three patients responded to the baseline questionnaire. One-hundred-and-twenty 
patients responded to the fi rst follow-up questionnaire after two weeks and were randomized. 
Finally, one hundred and two patients responded to the fi nal questionnaire after 11 weeks. 
Demographics
Demographic data are presented in table 1. The pain diagnoses generally included patients 
with radiculopathy, peripheral neuropathy, polyneuropathy and low back pain (supplemental 
table S1). The diff erent medications prescribed included NSAIDS, opioids, anticonvulsants and 
antidepressants (supplemental table S2).
Medication non-adherence
There were no diff erences in the rates of non-adherence (p=0.19), underuse (p=0.86) or overuse 
(p=0.06) between the three experimental groups. Details on medication non-adherence are 
presented in table 2.
Table 1. Demographics
Standard 
care
(n=40)
Intensive 
follow-up
(n=40)
Patient 
Initiated 
follow-up 
(n=40)
Age (mean (SD)) 59.7 (12,6) 54.3 (13,6) 55.7 (12,9) p=0.17
Gender (n (%)) Male 
Female
15 (37)
25 (63)
13 (33)
27 (67)
18 (45)
22 (55)
p=0.51
Level of education (n(%)) Primary education
Lower secondary education
Upper secondary education
Post-secondary non-tertiary education
Tertiary education
0 (0)
11 (28)
9 (22)
12 (30)
8 (20)
2 (5)
10 (25)
7 (17)
13 (33)
8 (20)
1 (2)
11 (27)
7 (18)
15 (38)
6 (15)
p=0.99
Mean Pain intensity (nRS) baseline mean (SD) 6.3 (1,7) 6.1 (1,7) 6.3 (1.8) p=0.85
Max Pain intensity (nRS) baseline mean (SD) 7.8 (1.4) 7.6 (1.3) 7.8 (1.4) p=0.90
number of diff erent medications (n (%)) 1
2
3
4
5 or more
4 (10)
4 (10)
3 (8)
5 (12)
24 (60)
6 (15)
4 (10)
8 (20)
5 (13)
17 (42)
5 (13)
0 (0)
2 (5)
9 (23)
24 (59)
p=0.13
Pain duration (n(%)) 0-3 months
3-6 months
6-12 months
1-2 years
2-3 years
3-5 years
more than 5 years
0 (0)
1 (2)
6 (15)
10 (25)
10 (25)
1 (3)
12 (30)
0 (0)
5 (13)
4 (10)
8 (20)
6 (15)
5 (12)
12 (30)
0 (0)
4 (10)
8 (20)
3 (8)
4 (10)
8 (20)
13 (32)
p=0.95
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Table 2. Nonadherence to pain medication in the study groups by moment of measurement.
11 weeks non-adherence
yes No Total
Standard Care
2 weeks non- 
adherence
yes 5 (14%) 4 (11%) 9 (25%)
no 2 (6%) 25 (69%) 27 (75%)
Total 7 (19%) 29 (81%) 36 (100%)
Intensive hospital-
initiated follow-up
2 weeks non- 
adherence
yes 0 (0%) 3 (9%) 3 (9%)
no 3 (9%) 28 (82%) 31 (91%)
Total 3 (9%) 31 (91%) 34 (100%)
Intensive patient-
initiated follow-up
2 weeks non- 
adherence
yes 5 (17%) 2 (7%) 7 (24%)
no 4 (14%) 18 (62%) 22 (76%)
Total 9 (31%) 20 (69%) 29 (100%)
11 weeks underuse
yes No Total
Standard Care 2 weeks underuse
yes 3 (8%) 3 (8%) 6 (17%)
no 2 (6%) 28 (78%) 30 (83%)
Total 5 (14%) 31 (86%) 36 (100%)
Intensive hospital-
initiated follow-up
2 weeks underuse
yes 0 (0%) 2 (6%) 2 (6%)
no 3 (9%) 29 (85%) 32 (94%)
Total 3 (9%) 31 (91%) 34 (100%)
Intensive patient-
initiated follow-up
2 weeks underuse
yes 3 (10%) 2 (7%) 5 (17%)
no 2 (7%) 22 (76%) 24 (83%)
Total 5 (17%) 24 (83%) 29 (100%)
11 weeks overuse
yes No Total
Standard Care 2 weeks overuse
yes 2 (6%) 1 (3%) 3 (8%)
no 1 (3%) 32 (89%) 33 (92%)
Total 3 (8%) 33 (92%) 36 (100%)
Intensive hospital-
initiated follow-up
2 weeks overuse
yes 1 (3%) 1 (3%)
no 33 (97%) 33 (97%)
Total 34 (100%) 34 (100%)
Intensive patient-
initiated follow-up
2 weeks overuse
yes 3 (10%) 0 (0%) 3 (10%)
no 2 (7%) 24 (83%) 26 (90%)
Total 5 (17%) 24 (83%) 29 (100%)
Across all study participants, general non-adherence rate before randomization after 2 weeks 
was 22%, underuse rate was 16% and overuse rate was 8%. Post-randomization non-adherence 
rate after 11 weeks was 19%, underuse rate was 13% and overuse rate was 8%. Overuse oc-
curred significantly more in opioid users (supplemental table S3). There was no difference in 
patterns of non-adherence in patients taking direct acting pain medications (NSAIDs, opioids, 
other pain medications) compared with patients taking anticonvulsants or antidepressants.
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Pain intensity
Mean pain intensities at baseline, 2 weeks and 11 weeks in the study groups are shown in fi gure 
1. There was no signifi cant group eff ect (p=0.46). Time eff ect was small but signifi cant (p=0.017) 
and consisted of an increase in mean pain intensity after 2 weeks followed by a decrease after 
11 weeks. Study allocation did not contribute to changes observed over time (Time*Group; 
p=0.98).
figure 1. Pain intensities (mean(SD)) in the study groups by moment of measurement.
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Maximum pain intensities are shown in figure 1. Factor time (p=0.28), group (p=0.27) and 
time*group were not significant. There was no significant difference between the groups 
(p=0.27), nor over time (p=0.28). Likewise, there was no significant interaction between the 
groups and time (p=0.51).
Pain treatment satisfaction
Results of the PTSS module ‘Satisfaction with information about pain and its treatment’ are 
presented in table 3. There was no significant effect of Time (p=0.13) or Group (p=0.54), but 
treatment allocation contributed significantly to the changes between week 2 and week 11 
(Time*Group; p=0.02). Results of the PTSS modules ‘Satisfaction with medical care’, ‘Satisfaction 
with the effect of current pain medication’ and ‘Satisfaction with current medication and care 
received’ are outlined in figure 2. No significant Time, Group, or Time*Group effects were ob-
served in these modules. Stand-alone PTSS questions regarding the general satisfaction about 
current pain medication, concordance between experienced and expected pain relief and the 
wish to continue current pain medication are outlined in figure 3. There were no significant 
differences found in the analyses of these items as well. A majority of patients suffered some 
side effects up to unacceptable side-effects. The reports of side effects at T2 are documented 
in table 4. 
figure 2. Results of the PTSS modules ‘Satisfaction with medical care’, ‘Satisfaction with the effect of cur-
rent pain medication’ and ‘Satisfaction with current medication and care received’(mean(SD)). Scores range 
from 1 (very satisfied) to 5 (very dissatisfied).
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number of contacts
Mean number of planned contacts were 2.9 (0.6), 5.4 (1.4) and 2.8 (0.6) in group S, INT and PI, 
respectively. Mean number of unplanned contacts were 0.5 (0.8), 0.3 (0.6) and 0.7 (2,0) in group 
S, INT and PI, respectively (p=0.38).
Table 3. Results of PTSS module ‘Satisfaction with information about pain and its treatment’.
Information Standard care Intensive follow-up Patient Initiated 
follow-up
Time*Group
Week 2
Preferred more 26 (70%) 26 (68%) 31 (82%)
F (2,89) = 4.1;
p=0.020
Enough 10 (27%) 11 (29%) 7 (18%)
Preferred less 1 (3%) 1 (3%) 0 
Week 11
Preferred more 26 (74%) 19 (58%) 16 (57%)
Enough 9 (26%) 14 (42%) 9 (32%)
Preferred less 0 0 3 (12%)
figure 3. Results of the PTSS stand-alone questions (mean(SD)). Scores range from 1 (very positive) to 5 
(very negative).
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DISCuSSIOn
Although we hypothesized that a more intensive follow-up regimen would lead to better 
medication adherence by increased support in the initial phase of pharmacological treatment, 
including a possibility to modify the prescribed therapy at an earlier phase, we did not find 
differences in adherence patterns between the study groups. An explanation might be that 
the content of follow-up contact is more important than the frequency of these contacts. The 
content of patients contacts was not controlled in this study. Secondly, intensified care might 
not be able to address all determinants that play a role in a complex behaviour as medication 
adherence. In other words, even when all health-care system related factors are optimized, 
patient-related, disease-related or socio-economic factors might still play an important role 
in adherence behaviour. These factors are not likely to be changed by an increased follow-up 
frequency. 
There were no differences in patient satisfaction regarding medication, the care provided 
or the effect of chronic pain treatment between the study groups. However, satisfaction re-
garding the provision of information did significantly differ over time: a negative change in 
the standard follow-up group compared to a positive change in both intervention groups. In 
the hospital-initiated follow-up group, this effect may be (partly) due to the increased number 
of contacts between patient and caregiver, in which additional information might have been 
acquired. However, this does not explain the changes in the patient-initiated care group, as the 
number of contacts were not increased compared to the standard care group. In both interven-
tion groups, the psychological effect of additional care and support, even if provided on an 
on-demand basis, might play a role. 
More than half of the patients suffered considerable side-effects. Side effects have been 
negatively associated with pain medication adherence.14,15 In a post-hoc multivariate regression 
analysis entering randomization and side effects as co-variables, side effects were contributing 
Table 4. Side effects of pain medication.
Side effects Standard care
Intensive follow-
up
Patient Initiated 
follow-up
Time*Group
2 weeks follow-up
none 10 (25%) 4 (10%) 9 (24%)
F(2,96)=0.47;
p=0.62
little 11 (27%) 8 (20%) 8 (21%)
some 13 (32%) 17 (42%) 13 (34%)
many 5 (13%) 8 (20%) 6 (16%)
unacceptable 1 (3%) 3 (8%) 2 (5%)
11 weeks follow-up
none 15 (42%) 5 (15%) 8 (28%)
little 5 (14%) 4 (12%) 5 (17%)
some 6 (17%) 15 (44%) 9 (31%)
many 8 (22%) 8 (23%) 5 (17%)
unacceptable 2 (5%) 2 (6%) 2 (7%)
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signifi cantly to underuse (p=0.005) and non-adherence after 11 weeks of therapy (p=0.033). 
Side eff ects may be one of the clues of the high rates of non-adherence in chronic pain patients, 
especially in the initial phase of pharmacological pain treatment. 
A disappointing fi nding was that pain intensities during the study did not improve, and that 
most patient satisfaction scores, although slightly positive, were far from optimal. Although most 
patients wanted to continue their therapy, the analgesic eff ects did not reach pre-conceived 
expectations. Although patient satisfaction scores regarding medical care were generally ac-
ceptable, satisfaction scores regarding the eff ects of medications were unsatisfactory. A reason 
for these fi ndings may be that patients, and caregivers possibly as well, tend to overestimate 
the ability for pain medication to improve pain intensity and quality of life. Furthermore, the 
common presence of side eff ects further aff ects patients’ perception of prescribed therapy. The 
fact that medication was not successful to relieve pain in many cases, stresses the importance 
to follow-up on patients to consider change or cessation of pharmacological therapy.
Intensifi ed hospital-initiated follow-up consisted of an increased number of contacts com-
pared to standard care, which might be a burden on health-care resources without evident 
clinical benefi t. Patient-initiated follow-up did not, contrary to our expectations, lead to a 
signifi cant increase in unplanned patient contacts. It must be kept in mind that we combined 
patient-initiated care with routine follow-up, as we thought it would be irresponsible to not 
systematically evaluate the eff ect of medication prescribed. Most other studies reporting 
patient-initiated care systems did incorporate an annual or biannual consultation as a safety-
net in the intervention groups as well.10 In the long course of therapy, patient-initiated therapy 
might be a good and cost-eff ective alternative for planned follow-up.9-11 Another advantage of 
patient initiated care might be that time and eff orts are spent to patients that actually need it.
An important limitation of our study is the relative short follow-up period of three months 
after prescription of pain medication. As chronic non-malignant pain therapy often involves 
chronic use of analgesics, a longer follow-up period, for example one year, in this study might 
have led to diff erent results. Whereas the intensifi ed follow-up strategy would not be sustain-
able for one year in clinical practice, the patient-initiated follow-up strategy would. A second 
limitation is that genuine patient-initiated care should lead to less planned contacts compared 
to standard care. Because of safety reasons, we chose to combine standard care with additional 
care on demand. Future studies should investigate the non-inferiority, or even superiority, of 
patient-initiated care outcomes during long-term pain therapy. A fi nal consideration is that, 
although the majority of patients suff ered from neuropathic pain, the study sample was a 
heterogeneous sample with diff erent medications prescribed. However, with the exception of 
an association with opioid use and overuse of medication, associations between diff erent types 
of medication and adherence behaviour have not been reported.5 
In conclusion, intensive hospital-initiated follow-up of chronic pain patients or patient-
initiated follow-up following prescription of pain medication did not result in better medica-
tion adherence compared to standard care. Although these strategies led to higher patients’ 
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satisfaction regarding information provision, other satisfaction scores did not differ from 
standard care. Whereas a planned intensive follow-up strategy automatically led to increased 
number of contacts, and therefore costs, the patient-initiated follow-up strategy did not. As 
patient initiated follow-up is an upcoming care model in the management of other chronic 
diseases, it might be considered for chronic pain management as well. 
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SuPPLEMEnTAL MATERIAL
Table S1. Pain diagnoses
Pain Diagnosis
Standard care 
(n=40)
Intensive follow-up
(n=40)
Patient Initiated 
follow-up (n=40)
Central pain 0 (0) 2 (5) 1 (2)
Polyneuropathy 4 (10) 7 (18) 9 (23)
Peripheral neuropathy 8 (20) 11 (28) 7 (18)
 Post-herpetic neuralgia 2 (5) 1 (2) 0 (0)
 Post-surgical neuralgia 2 (5) 6 (15) 3 (8)
 Post-traumatic neuralgia 1 (2) 2 (5) 1 (2)
 Other 3 (7) 2 (5) 2 (5)
Radiculopathy 16 (40) 13 (33) 7 (17)
 Cervical 4 (10) 1 (2) 1 (2)
 Thoracic 0 (0) 0 (0) 1 (2)
 Lumbar (herniated disc/canal stenosis) 5 (13) 4 (10) 1 (2)
 Lumbar (failed back surgery syndrome) 7 (17) 8 (20) 4 (10)
facial Pain 2 (5) 3 (7) 1 (2)
Low back Pain 4 (10) 3 (7) 6 (15)
CRPS 4 (10) 1 (2) 3 (8)
fibromyalgia 1 (2) 0 (0) 4 (10)
Distal arthropathy 1 (2) 0 (0) 2 (5)
Table S2. Prescribed medications at 2 weeks follow up and 11 weeks follow-up.
2 weeks 11 weeks
Standard
care
(n=40)
Intensive
follow-up
(n=40)
Patient
initiated
follow-up
(n=40)
Standard
care
(n=37)
Intensive
follow-up
(n=34)
Patient 
initiated 
follow-up
(n=30)
non-opioids
NSAIDs 3 (8) 3 (8) 1 (2) 1 (3) 2 (6) 1 (3)
Anti-convulsants 17 (42) 9 (22) 6 (15) 13 (35) 10 (29) 7 (23)
Anti-depressants 5 (12) 8 (20) 7 (18) 5 (13) 2 (6) 3 (10)
Other 3 (8) 1 (2) 2 (5) 4 (11) 0 (0) 1 (3)
Anti-convulsants & anti-depressants 2 (5) 2 (5) 1 (2) 3 (8) 3 (9) 2 (7)
Other combinations of non-opioids 1 (2) 1 (2) 1 (2) 1 (3) 1 (3) 0 (0)
Opioids
Oxycodone/ Tapentadol/ Fentanyl/ 
Tramadol
3 (7) 5 (13) 8 (20) 6 (16) 9 (26) 7 (23)
Opioids and non-opioids
Opioids & anticonvulsants 2 (5) 2 (5) 3 (8) 1 (3) 3 (9) 2 (7)
Opioids & antidepressants 1 (3) 4 (10) 2 (5) 3 (8) 2 (6) 1 (3)
Opioids & NSAIDs 2 (5) 1 (3) 3 (8) 0 (0) 1 (3) 3 (10)
Other combinations of opioids and 
non-opioids
1 (3) 4 (10) 6 (15) 0 (0) 1 (3) 3 (10)
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Table S3. Type of medication and frequency of non-adherence at T2
Opioids non-opioids p
Non-adherence n (%) 10 (24) 9 (15) 0.27
Underuse n (%) 5 (12) 8 (14) 0.82
Overuse n (%) 7 (17) 1 (2) 0.006
Anti-convulsants & anti-depressants Direct-acting pain medication
Non-adherence n (%) 11 (17) 8 (23) 0.49
Underuse n (%) 8 (12) 5 (14) 0.80
Overuse n (%) 4 (6) 4 (11) 0.36
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AbSTRACT
background
Non-adherence to prescribed pain medication is common in chronic non-malignant pain pa-
tients. Beliefs about pain medication have been reported to be associated with non-adherence 
behaviour in cross-sectional studies. The aim of this study was to prospectively investigate the 
relation between patients’ beliefs about pain medication and their medication adherence and 
treatment outcome.
Methods
Chronic non-malignant pain patients completed a baseline questionnaire including the 47-
item Pain Medication Attitudes Questionnaire (PMAQ), consisting of seven subscales regarding 
beliefs on prescribed medication. After 11 weeks, medication underuse and overuse were as-
sessed by self-report. In addition, patient satisfaction regarding the prescribed medication and 
the presence of side effects were assessed.
Results
One hundred thirty three participants completed the baseline questionnaire, and 99 patients 
completed the follow-up questionnaire after 11 weeks. Concerns over side effects at baseline 
were positively associated with underuse after 11 weeks. Perceived need was positively as-
sociated with overuse. Concerns over side effects and mistrust in the doctor at baseline were 
negatively associated with patient satisfaction regarding prescribed medication after 11 weeks, 
and concerns over side effects and concerns over withdrawal were positively associated with 
presence of side effects after 11 weeks. Forty-two percent of patients were satisfied with pre-
scribed medication. Fifty-eight percent of patients were moderately to extremely bothered by 
side effects.
Conclusion
Attitudes and concerns towards pain medication are associated with adherence patterns and 
outcome parameters. In order to improve medication adherence and therapy outcome, patient 
beliefs about pain medication should be taken into account. 
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InTRODuCTIOn
The prescription of medication is fundamental to medical management of most long-term 
conditions, including chronic non-malignant pain. However, many patients do not take their 
medication as prescribed, representing a failure to translate potentially eff ective therapy into 
optimal outcomes for patients and society.1 
Adherence to a medial regime is defi ned as the extent to which a person’s behaviour cor-
responds with agreed recommendations from a health care provider.2 Nonadherent behaviour 
may be intentional, unintentional, or both. Unintentional nonadherence occurs when a patient 
wants to adhere but is unable to because of lack of capacity or resources. Intentional nonad-
herence involves a decisional process not to follow recommendations. Individual perceptions 
about disease severity or prescribed therapy can infl uence motivation to start or continue 
medication.3,4 Beliefs about medication are a well-investigated determinant of medication 
adherence in many chronic conditions.3,4 The individual balance between perceived necessity 
and concerns about medication (the ‘Necessity-Concerns Framework’) may explain intentional 
nonadherence and provides a target for adherence-improving interventions.4
Perceived necessity and concerns towards pain medication have also been described to be 
associated with adherence in chronic non-malignant pain patients.5,6 Using the 47-item ‘Pain 
Medication Attitudes Questionnaire (PMAQ), perceived need was associated with analgesic 
overuse among chronic pain patients, and concerns over addiction and side eff ects were as-
sociated with underuse of pain medication in chronic pain patients.5 Recently, a 14-item version 
of the PMAQ showed similar results.7 
Beliefs about medications for chronic disease have been described to be related to therapy 
outcome, for example in diabetes, possibly by their eff ect on medication adherence.8 It is un-
known whether this applies to chronic pain treatment outcomes as well.
Earlier cross-sectional studies reported a relationship between patients beliefs about pain 
medication and medication adherence. The aim of this study was to prospectively investigate 
the relation between initial patients’ beliefs about pain medication and medication adherence 
patterns and treatment outcomes during follow-up. 
METhODS
This study was part of a randomized clinical trial, in which the eff ect of three diff erent follow-up 
strategies on medication adherence and treatment outcome were compared. Methods have 
been described in detail in a previous report. Briefl y, this single-center randomized controlled 
trial was performed in a pain treatment center of a large general hospital in the Netherlands 
after approval of the medical ethics committee. All patients with non-malignant pain existing 
longer than 3 months who received a new analgesic prescription or who received additional 
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pain medication to an existing treatment regimen, were invited to participate. Participants 
had to be able to complete electronic questionnaires in the Dutch language. Patients receiv-
ing medication on an ‘as needed’ basis and patients younger than 18 years were excluded. All 
participants provided written informed consent.
Procedures
After receipt of informed consent an email was sent containing a link to the web-based baseline 
questionnaire. After eleven weeks, a follow-up questionnaire was sent. 
Patients were randomized to one of the three study groups: (1) standard follow-up, which 
consisted of follow-up visits after 6 and 12 weeks; (2) intensified hospital-initiated follow-up, 
which consisted of standard follow-up and additional scheduled counselling by a specialized 
nurse after 3, 5, 8 and 10 weeks; or (3) patient-initiated follow-up, which consisted of standard 
follow-up and additional counselling at patients’ request. 
Outcome measures
Baseline data collected were: age, gender, level of education, mean and maximum pain inten-
sity in the previous week (11-point numeric rating scale (NRS)), number of different medications 
and duration of pain symptoms. Patient attitudes and concerns about pain medication were 
measured with a Dutch translation of the ‘Pain Medication Attitudes Questionnaire (PMAQ)’, a 
47-item validated survey measuring attitudes and concerns towards pain medication regard-
ing seven subscales (perceived need, mistrust in the prescribing doctor, and concerns over 
side-effects, adverse scrutiny, withdrawal symptoms, addiction and tolerance).5 The English 
questionnaire was translated forward by two persons, one of whom was not related to the 
study. Two other persons performed backward translation, one of whom was not related to the 
study and had English as his native language. 
Medication adherence was measured 11 weeks after initiation of the new prescription. 
Adherence was measured by asking two questions. One question measured underuse of pain 
medication: ‘You received a prescription for pain medication from your doctor. How often do 
you, intentionally or unintentionally, miss or skip a dose? ’. The second question measured over-
use of pain medication: ‘How often do you take more medication than prescribed? Answers 
were given on a 6 point scale (0=never, 1=seldom, 2= once a month, 3=once a week, 4 more 
than once a week, not every day, 5=every day).
Also after 11 weeks, patient satisfaction with current medication was measured (1=very 
satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied) as 
part of a more extensive questionnaire, the Dutch translation of the Pain Treatment Satisfac-
tion Scale (PTSS; MAPI institute, Lyon, France).9 Because we did want to study the relationship 
between attitudes towards medication and satisfaction with this medication, we did not use 
the data of the other modules measuring satisfaction with other aspects of care. Furthermore, 
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the burden of side eff ects was registered (1=no side eff ects, 2=a little bothered, 3=moderately 
bothered, 4=quite bothered and 5= extremely bothered). 
Data analysis
Underuse was defi ned as missing a dose every week up to every day. Overuse was defi ned as 
taking additional medication every week up to every day. 
PMAQ items were rated on a 6-point numerical scale (0=never true to 5=always true). One 
missing value per subscale was accepted, in which case the mean score of valid item scores 
were used. For the regression analysis, overall satisfaction with current pain medication scores 
was dichotomized, considering scores of 3 and higher as ‘not satisfi ed’. Side eff ects were di-
chotomized for the regression analysis as well, considering scores of 3 and higher as ‘bothered 
by side eff ects’.
Statistical analysis
Descriptive statistics were used to determine the frequencies of the demographic variables 
and PMAQ scores and to describe measures of central tendency and dispersion dependent 
on the shape of their distribution. The Shapiro-Wilk test was used to analyse whether or not 
parameters were normally distributed. Normally distributed data are presented as mean (SD), 
not normally distributed data as median (IQR). Binary logistic regression analysis was used to 
evaluate the contribution of PMAQ-subscores to the prediction of adherence, treatment satis-
faction and side eff ects 11 weeks after initiation of the newly prescribed medication. To prevent 
overfi tting of the model, we performed univariate binary logistic regression analyses of PMAQ 
subscales. Only those parameters with a signifi cance level of p ≤ 0.2 were entered into the fi nal 
multivariate stepwise binary logistic regression analysis (method Backward Wald) with a prob-
ability out of p=0.1. To prevent multicollinearity, pairwise correlations between the parameters 
to be entered into the fi nal model were calculated. Of those with a bivariate correlation of ≥ 
0.7 only the parameter with the highest univariate signifi cance level was entered into the fi nal 
model. 
For all statistics, alpha was set at the traditional 0.05 level. All analyses were performed using 
IBM SPSS Statistics version 24 (SPSS, Inc, Chicago, IL).
RESuLTS
From November 2014 up to November 2016, one hundred thirty-three patients completed 
the baseline questionnaire. After 11 weeks, 99 patients (75%) completed the study. Baseline 
characteristics of these patients are presented in table 1.
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Table 1. Demographics
n=99
Age (median (IQR)) 60 (21)
Gender (n (%))
Male 36 (36)
Female 63 (64)
Level of education (n(%))
Primary education 2 (2)
Lower secondary education 28 (28.3)
Upper secondary education 19 (19.2)
Post-secondary non-tertiary education 39 (39.4)
Tertiary education 11 (11,1)
Mean Pain intensity (nRS) baseline median (IQR) 7.0 (2,0)
Max Pain intensity (nRS) baseline median (IQR) 8.0 (2,0)
number of different medications (n (%))
1
2
3
4
5 or more
11 (11)
6 (6)
9 (9)
16 (16)
57 (58)
Pain duration (n(%))
0-3 months
3-6 months
6-12 months
1-2 years
2-3 years
3-5 years
more than 5 years
0 (0)
10 (10)
15 (15)
16 (16)
15 (15)
10 (10)
33 (34)
There were no differences found between the study arms (standard follow-up, intensive 
hospital-initiated follow-up and patient-initiated follow up) regarding underuse of medication, 
overuse of medication, PTSS-modules (except satisfaction with information provided) and 
presence of side effects. 
Patients’ attitudes towards pain medication
Median scores (IQR) of the seven PMAQ subscales of study participants were as follows: con-
cerns over addiction 1.2 (1.0); perceived need 2.6 (0.9); concerns over scrutiny 0.9(0.9); concerns 
over side effects 2.0 (0.9); concerns over tolerance 1.8 (1.1); mistrust in the prescriber 1.9 (0.8); 
concerns over withdrawal symptoms 1.3 (0.7) (figure 1). 
Medication adherence, patient satisfaction and side effects
Underuse was reported by 13 (13.1%) patients and overuse by 8 (8.1%) patients. Patients’ sat-
isfaction scores with current medication were as follows: 8 (8.1%) patients were very satisfied, 
34 (34.3%) patients were satisfied, 32 (32.2%) patients were neither satisfied nor dissatisfied, 20 
(20.2%) patients were dissatisfied and 5 (5.1%) patients were very dissatisfied. Presence of side 
effects were scored as follows: 28 (28.3%) patients had no side effects, 14 (14.1%) were a little 
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bothered, 30 (30.3%) were moderately bothered, 21 (21.2%) were quite bothered and 6 (6.1%) 
patients were extremely bothered by side eff ects.
figure 1. Boxplot of the subscales of the Pain Medication Attitudes Questionnaire scores (0=never true op 
to 5=always true).
Attitudes and concerns towards medication and underuse 
The univariate binary logistic regression analyses revealed that only concerns over addiction 
(p=0.10), concerns over side eff ects (p=0.002) and concerns over withdrawal (p=0.027) signifi -
cantly contributed to the prediction of medication underuse. Entering the above-mentioned 
parameters into the fi nal multivariate binary logistic regression analysis resulted in a signifi cant 
contribution of concerns over side eff ects to the prediction of medication underuse (p=0.003) 
(table 2A). The sensitivity (69.2%), specifi city (80.7%), and overall classifi cation (79.2%) were 
high using a cut-off  value of 0.85. The ROC curve is presented in fi gure 2A.
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Table 2A. Results of the multivariate binary logistic regression analysis of underuse.
95% CI for Odds Ratio
Included B (SE) [p-value] Lower Odds Ratio Upper
Constant 5.99 (1.51) [<0.001]
Concerns over side effects - 1.27 (0.43) [0.003] 0.12 0.28 0.65
Note: R2 = 0.10 (Cox & Schnell), 0.18 (Nagelkerke). Model χ2(1) = 9.98, p=0.002
figure 2A. Receiver operating characteristic curve of concerns over side effects as a predictor of underuse 
non-adherence (underuse versus no underuse). Area under the curve 0.754 (SE 0.079), p=0.003.
Attitudes and concerns towards medication and overuse 
Both perceived need (p=0.015) and concerns over side effects (p=0.128) significantly contrib-
uted to the prediction of overuse in the univariate logistic regression. In the final multivariate 
analysis, only perceived need significantly contributed to the prediction of medication overuse 
(p=0.015) with a sensitivity of 62,5%, specificity of 87,5% and overall classification of 85,5% 
using a cut off value of 0.92 (table 2B). The ROC curve is presented in figure 2B.
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figure 2b. Receiver operating characteristic curve of perceived need as a predictor of overuse non-adher-
ence (overuse versus no overuse). Area under the curve 0.776 (SE 0.094), p=0.01.
Attitudes towards pain medication and satisfaction with medication
Concerns over scrutiny (p=0.11), concerns over side eff ects (p=0.07), concerns over tolerance 
(p=0.07), mistrust in the doctor (0.05), concerns over withdrawal (p=0.037) were signifi cantly 
associated with satisfaction with prescribed medication in the univariate analysis. Entering 
these items into the multivariate analysis resulted in a signifi cant contribution of mistrust in 
the prescribing doctor (p=0.035) and concerns over side eff ects (p=0.076) to the prediction of 
satisfaction (sensitivity 77,4%, specifi city 52,4% and overall classifi cation of 66,3% with a cut of 
value of 0.5) (table 2C). The ROC curve is presented in fi gure 2C. 
Table 2b. Results of the multivariate binary logistic regression analysis of overuse.
95% CI for Odds Ratio
Included B (SE) [p-value] Lower Odds Ratio Upper
Constant 10.53 (3.53) [0.003]
Perceived Need - 2.08(0.87) [0.015] 0.02 0.12 0.66
Note: R2 = 0.08 (Cox & Schnell), 0.18 (Nagelkerke). Model χ2(1) = 7,70, p=0.006
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Table 2C. Results of the multivariate binary logistic regression analysis of satisfaction about prescribed 
medication.
95% CI for Odds Ratio
Included B (SE) [p-value] Lower Odds Ratio Upper
Constant 4.27 (1.69) [0.011]
Concerns over side effects - 0.54 (0.30) [0.076] 0.32 0.58 1.06
Mistrust in the doctor - 1.01 (0.48) [0.035] 0.14 0.36 0.93
Note: R2 = 0.08 (Cox & Schnell), 0.11 (Nagelkerke). Model χ2(2) = 8,11, p=0.017
figure 2C. Receiver operating characteristic curve of concerns over side effects and mistrust in the doctor 
as a predictor of patient satisfaction about prescribed medication (satisfied versus not satisfied). Area under 
the curve 0.671 (SE 0.056), p=0.04.
Attitudes towards pain medication and presence of side effects
Concerns over scrutiny (p=0.121), concerns over side effects (p=0.005), concerns over with-
drawal (p=0.022), mistrust in the doctor (p=0.141) and concerns over tolerance (p=0.082) were 
associated with the presence of side effects after 11 weeks. Entering these items into the multi-
variate analysis resulted in a significant contribution of concerns over side effects (p=0.032) and 
concerns over withdrawal (p=0.10) to the prediction of side effects after 11 weeks (sensitivity 
65,5%, specificity 63,4% and overall classification of 64,6% with a cut of value of 0.55) (table 2D). 
The ROC curve is presented in figure 2D. 
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Table 2D. Results of the multivariate binary logistic regression analysis of presence of side eff ects.
95% CI for Odds Ratio
Included B (SE) [p-value] Lower Odds Ratio Upper
Constant - 3.30 (1,20) [0.006]
Concerns over side eff ects 0.71 (0.34) [0.035] 1.05 2.04 3.96
Concerns over withdrawal 0.64 (0.38) [0.094] 0.90 1.90 4.01
Note: R2 = 0.11 (Cox & Schnell), 0.14 (Nagelkerke). Model χ2(2) = 10.61, p=0.005
figure 2D. Receiver operating characteristics curve of concerns over side eff ects and concerns over with-
drawal as a predictor of side eff ects (side eff ects versus no side eff ects). Area under the curve 0.681 (SE 
0.054), p=0.002.
DISCuSSIOn
This prospective study confi rms results of earlier cross-sectional studies, in which associations 
were found between patient beliefs about prescribed medication and medication adher-
ence.5 As previously discussed, underuse and overuse are two diff erent entities that should be 
considered separately.6,10 This is confi rmed by the fact that diff erent beliefs about medication 
contribute to these behaviours. Underuse non-adherence was associated with concerns over 
side eff ects of pain medication. This eff ect was independent of the actual presence of side ef-
fects, as verifi ed by a post-hoc binary regression analysis entering concerns over side eff ects 
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(p=0.024) and presence of side effects (p=0.030) as covariates. Overuse non-adherence was 
associated with perceived need for pain medication. In the earlier study in which the PMAQ was 
used in secondary care, other PMAQ subscales were demonstrated to be associated with unde-
ruse (concerns over withdrawal, perceived need) and overuse (concerns over scrutiny) as well.5 
Although directions of the associations were similar, these factors did not reach significance in 
our study. A possible explanation might be the different definition of underuse and overuse. 
Instead of considering any deviation from the prescription as nonadherence, in our study 
patients were allowed to deviate from the prescription up to once a week to be considered 
adherent. 
Negative beliefs and concerns about pain medication during initiation of pharmacological 
therapy were related to treatment outcome. Mistrust in the doctor was negatively associated 
with patient satisfaction with prescribed medication. Initial mistrust seems to have an effect 
on satisfaction after three months, indicating the importance of building on a good patient-
provider relationship from the initial visit onwards. Patient education, shared decision making, 
and affective communication are behaviours that might enhance the relationship and thereby, 
treatment effectivity. Concerns over side effects during initiation of therapy were negatively as-
sociated with satisfaction with prescribed medication. This finding is not surprising, as concerns 
over side effects predicted the actual presence of side effects. Side effects are well known to 
have an important negative impact on treatment outcome of pharmacological pain therapy. 
The finding that patients’ concerns over side effects were associated with presence of side ef-
fects after 11 weeks, might be explained by earlier negative experiences with pain medication. 
Chronic pain patients referred to secondary care have often been treated with medications 
before. Side effects may not only occur due to intolerance to a specific drug, but also due to 
impaired drug metabolism caused by decreased liver or renal function, or due to interactions 
with other medications. For this reason, patients with earlier negative effects of pain medi-
cation might be more susceptible for repeated suffering from side effects. However, another 
explanation might be that patients who are worried about side effects of medication are more 
alert to detect and suffer from negative effects of medications. 
The non-adherence levels found in this study were lower than reported in earlier studies. 
Firstly, this might be due to the measurement of adherence we selected consisting of one 
question regarding underuse and one regarding overuse of medication. Although it was used 
anonymously, and patients did not have a reason to report different than their actual medica-
tion use, this self-report measure is susceptible to overestimation of adherence, because of 
social desirability and memory biases.11 Secondly, patients were allowed to deviate from the 
prescription up to once a week to be considered adherent. Other studies use a more strict 
definition of non-adherence as ‘any deviation of prescribed therapy’. Up to now, there is no 
generally accepted definition of adherence and no general accepted subjective or objective 
operationalisation of this concept. We chose this self-report measure because it is clinically 
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applicable, and this defi nition because it seems unrealistic to expect patient to never, intention-
ally or unintentionally, omit or add a dose.
Findings about associations between patient views about medication and medication ad-
herence are clinically relevant and should support the design of future adherence-improving 
interventions. Taking account of patients’ necessity beliefs and concerns about pain medication 
when prescribing new analgesics could enhance adherence to these prescriptions. The fi rst 
step in facilitating adherence is to take a ‘no-blame approach’ and encourage an honest and 
open discussion to identify barriers to adherence.12 Individual beliefs and concerns should be 
addressed, leading to a shared decision regarding pharmacological therapy. This approach, 
which has had encouraging results 13, might lead to alternate (or no) treatment when specifi c 
barriers are too strong to overcome. The most challenging reality is that thorough assessment 
and discussion of patients’ views about medication costs signifi cant time, and is diffi  cult to 
achieve during a busy schedule at a pain clinic. Given the fi nding that physicians generally take 
less than a minute to prescribe new medication, there is a need for change.14 Questionnaires 
as the PMAQ, of which a shorter 14-item form has been introduced recently, might serve as a 
starting point for discussions about pain medication. Although standardized education might 
increase patient knowledge, tailored counselling is necessary to address specifi c concerns that 
are highly individual.15
A limitation of this study might have been the fact that it is a sub-study within a randomized 
trial which investigated the eff ect of diff erent follow-up strategies on medication adherence 
and pain treatment satisfaction. However, the study allocation did not contribute to any of the 
outcome parameters used in this study. Furthermore, in a post-hoc analysis (data not shown), 
we entered randomization as a covariate, with identical results of the multivariate regression 
analysis. Secondly, the follow-up period after initiation of chronic pain therapy in this study 
was only eleven weeks, which may account for the relatively low non-adherence rates. It is 
likely that non-adherence rates would have been higher after, for example, six months. A fi nal 
limitation is the dropout rate of 25%, for which the reasons were not recorded. Patients wo do 
not adhere to a study protocol which consists of the completion of three questionnaires might 
have diff erent medication adherence patterns as well. 
In conclusion, this study prospectively confi rms earlier cross-sectional reports about the 
association between attitudes towards prescribed pain medication and non-adherence pat-
terns. Furthermore, attitudes and concerns towards pain medication were related to outcome 
parameters. In order to improve medication adherence and therapy outcome, patient beliefs 
about pain medication should be addressed. 
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AbSTRACT
Objective
Non-adherence to pain medication is common in chronic pain patients and may result in 
unfavorable treatment outcome. Interventions to improve adherence behavior often fail to 
significantly change medication use. In this report we describe the application of a theoretical 
psychological model of behavior change in order to design an intervention to improve medica-
tion adherence in chronic pain patients. 
Methods
This study applies the Behavior Change Wheel framework and the Behavior Change Techniques 
Taxonomy to design a theory-based intervention to improve pain medication use. Available 
literature was used to extract determinants of adherence in chronic pain patients.
Results
Selected target behaviors to improve medication adherence are: share agreement on follow up 
policy, monitor medication adherence, provide patient education routinely, discuss attitudes 
and concerns towards pain medication, develop medication taking habits and use medication 
reminders. The intervention consists of three components in which relevant behavior change 
techniques are applied: (1) changes in the electronic patient data management systems to 
enable medical staff to apply target behaviors; (2) bi-annual education of medical staff to com-
mit the team to the proposed intervention and provide feedback; (3) routine and mandatory 
education of chronic pain patients following prescription of pain medication.
Conclusions
To improve medication adherence in chronic pain patients, most interventions should be 
focused on providers of pain therapy. Prescribing chronic pain medication should be seen as 
part of a larger treatment regimen including adequate follow-up, adherence monitoring and 
patient education during the course of treatment.
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InTRODuCTIOn
Chronic pain is a common medical condition aff ecting approximately 20 percent of the Euro-
pean adult population.1 In addition to the physical and emotional burden it brings, the fi nancial 
cost to society is huge, currently estimated at more than €200 billion per annum in Europe 
and $150 billion per annum in the USA.2 Although treatment often requires a multidisciplinary 
approach, pharmacological treatment remains one of the cornerstones of chronic pain man-
agement. However, the response to chronic drug treatment is often poor and highly variable.3 
There are several variables reasons for this variability. Age, gender, ethnicity and actual level of 
stress, mood or diseases may modify pain perception, and pharmaco-genetic diff erences result 
in a variable response to pain medication.4 Non-adherence to pain medication is also thought 
to play a role in the sub-optimal eff ect of analgesic therapy. Up to 40% of chronic pain patients 
do not use their medication as prescribed.5,6 Non-adherence in other types of chronic diseases 
resulted in reduced clinical benefi t, avoidable morbidity and mortality, medication wastage 
and increased medical costs.7 Furthermore, it could bias the assessment of treatment effi  cacy. 
The consequences of non-adherence in chronic pain patients are less clear. An association 
between pain medication adherence and treatment outcome has been shown, but a causal 
relationship has never been demonstrated.8 However, it seems plausible that some degree of 
pain medication adherence is necessary to maximize treatment eff ect and reduce the burden 
of side-eff ects as well. 
Interventions designed to improve medication adherence in chronic disease have mostly 
been described to be ineff ective or very complex, making it diffi  cult to be carried out in a 
non-research setting.9 Most of these interventions were developed without a sound theoretical 
base. Although medication adherence research has provided several factors associated with 
adherence, the application of these data to improve medication taking is limited. 
Theoretical psychological models explaining human behavior provide insight in the 
mechanisms involved in behavior change.10 In this study, we use the ‘Behavior Change Wheel’ 
(BCW) framework as a systematic approach to propose an intervention designed to improve 
medication adherence (fi gure 1).11,12 The BCW is designed to move from a behavioral analysis 
of the problem to evidence-based intervention design. Incorporated in this approach is the 
COM-B model of behavior that makes it possible to identify what needs to change in terms of 
capability (C), opportunity (O) and motivation (M), to actually achieve the desired behavioral 
change.12 Complementing the BCW framework is the Behavior Change Techniques Taxonomy. 
The taxonomy describes 93 specifi c behavior change techniques and allows for standardized 
reporting of interventions.
The aim of this study was to design a theory-based, practicable intervention to improve 
medication adherence in chronic non-malignant pain patients. 
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figure 1. The behavior change wheel. From: Michie, van Straalen, West, 2011.10 Licensed under CC BY 
(https://creativecommons.org/licenses/by/2.0/).
ThE InTERvEnTIOn DESIGnInG PROCESS
Application of the BCW framework is outlined in a guidebook that contains a series of work-
sheets based on eight steps.11 The process involved three stages encompassing the eight 
distinct steps (figure 2). The initial step in this approach is to identify the problem behavior (1), 
followed by selection of target behaviors, i.e. behaviors to be changed (2). The selection is based 
upon relevant scientific evidence. Target behaviors have to be specified as much as possible (3). 
The next step is to analyze what needs to change using the COM-B model: e.g., is greater Capabil-
ity, more Opportunity and/or stronger Motivation required (4)? Having identified this, the BCW 
is used to analyze how to achieve these changes, e.g. by education, training or environmental 
changes (5). Then, what policies, e.g. legislation or service provision, might facilities these 
changes (6). The following step is to select the ‘active ingredients’, from the behavior change 
techniques taxonomyV1 containing 93 techniques to change behavior (7).13 Finally, the best 
way to deliver the intervention has to be chosen, e.g. by face-to-face contact or mass-media 
campaign, once or repeatedly (8). 
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figure 2. The intervention design process. From: Michie, Atkins and West, 2014.11 Licensed under CC-BY 
(http://creativecommons.org/licenses/by/4.0/).
At the center of the BCW framework is the COM-B model (fi gure 3).12 This model recognizes 
that each behavior is the result of an interaction between its behavioral components, namely 
capability, opportunity and motivation. It can provide explanations why specifi c recommended 
behaviors are not engaged in. Changing behavior will involve changing one or more of these 
components and its sub-components:
- Capability, the individuals capacity to engage in the behavior, is subdivided into physical 
capability (physical skills or strength for a behavior) and psychological capability (psycho-
logical skills or knowledge to perform behavior).
- Motivation, all brain processes that energize and direct behavior, is subdivided into refl ec-
tive motivation (conscious processes involving plans and evaluations) and automatic moti-
vation (automatic processes involved in performing behavior, such as habits and emotional 
responses). 
- Opportunity, all factors lying outside the patient that make performance of the behavior 
possible or prompt it, is subdivided into physical opportunity (opportunity provided by the 
environment, including time and resources), and social opportunity (opportunity aff orded 
by interpersonal infl uences).
1. Identifi cation of the problem behavior
The problem behavior is non-adherence to prescribed pain medication in chronic pain patients. 
As medication adherence was defi ned as ‘taking medication as prescribed’ the intervention to 
be proposed is intended to address both underuse and overuse of pain medication. Aberrant 
use or abuse of pain medication falls outside the scope of this study, as it is a separate problem 
behavior with its own separate risk factors. As diff erent medications are associated with diff er-
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ent adverse effects and patient concerns, the intervention should be able to address the differ-
ences between, for example, opioids, anticonvulsants and NSAIDs. In addition, the intervention 
should primarily fit within the context of a secondary pain treatment center. 
u Capability 
Motivation 
Opportunity 
Behaviour 
figure 3. The COM-B model of behavior. From: Michie, van Straalen, West, 2011.10 Licensed under CC BY 
(https://creativecommons.org/licenses/by/2.0/).
2. Selection of target behaviors
Earlier, we performed a systematic literature review to identify determinants of medication 
adherence in chronic pain patients.6 In this review, determinants were extracted from 19 stud-
ies. Four independent pain physicians (including the first author) translated this determinants 
into potential target behaviors that might improve medication adherence (table 1). These 
potential target behaviors were judged on their likelihood to have an impact on adherence, the 
likelihood that the behavior can actually be performed, the possibility that the behavior has an 
impact on other (target) behaviors (spillover score), and the possibility to measure the behavior. 
Judging resulted in a rating of each item as very promising, promising , unpromising but worth 
considering or as unacceptable. Secondly, discrepancies were discussed until consensus was 
reached. Finally, most promising target behaviors to improve adherence were selected in this 
consensus meeting (supplemental table S1).
Final selected target behaviors:
- Shared agreement on follow-up policy, i.e. a clear and documented follow-up agreement that 
corresponds with individual patient expectations during analgesic treatment, was judged a 
reasonable target to improve a doctor-patient relationship (e.g. ‘shall we discuss the effect 
of your medication within four weeks?’, ‘would you prefer to call or visit the hospital?’). 
- Active monitoring and recording medication adherence, and communicating to do so, was 
considered a second target that has shown its benefit in earlier studies.14 
- Patient education to provide necessary knowledge of chronic pain and analgesic treatment 
and discussion of individual attitudes and concerns (‘what do you think about taking pain 
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medication?’) about pain medication were selected as target behaviors of health care 
providers. Several patient factors have been reported to predict adherence behavior.6 The 
way people think about their condition and proposed therapy, including specifi c fears and 
concerns towards prescribed therapy have been consistently associated with adherence 
behavior.15,16 
- In patients, the formation of habits and the use of reminders to take medication were chosen 
target behaviors. Reminders have been previously reported to improve medication adher-
ence.17 
Table 1. Determinants of pain medication adherence and potential target behaviors to change adherence 
behavior. Target behaviors judged most promising are presented in bold.
Determinants of Pain Medication Adherence Potential Target behaviors
- Age
- Pain Intensity
- Active coping strategies
- Dosing frequency
- Polymedication
- Psychiatric disease
- History of drug abuse
- Quality of patient-caregiver relationship
- Active adherence monitoring strategies
- Knowledge and perceptions of disease severity
-  Knowledge, attitudes and concerns towards pain 
medication
• perceived need for pain medication
• fear of withdrawal symptoms
• fear of addiction
• fear of side eff ects
• fear of adverse scrutiny 
- Stimuli or cues to take medication (daily)
- Avoid high dosing frequency
- Avoid polymedication
- Rethink prescribing pain medication in psychiatric patients
-  Rethink prescribing pain medication in patients with a history of drug 
abuse
- Optimize patient caregiver relationship by routinely:
• Share decision making
• Defi ne goal and time frame to reach goal
• Share agreement on follow up policy
- Monitor medication adherence
- Educate patients
- Educate patients
- Address and discuss attitudes and concerns towards pain medication
- habit formation
- use reminders to use medication
- Self-monitoring of adherence
Other potential target behaviors were considered less promising. Although shared decision 
making concerning medical treatment might improve the doctor-patient relationship and 
thereby support adherence, it seems diffi  cult to realize and measure this in each individual 
patient-doctor consultation. The same holds true for ‘defi ning goal and time frame to reach goal’. 
The avoidance of high dosing frequency might be diffi  cult to achieve as well, and the avoidance 
of polymedication is frequently impossible because of comorbidity. Although alertness is justi-
fi ed, it is not possible to refrain from prescribing pain medication to all patients with a history of 
psychological distress or alcohol abuse, as this is a common situation in chronic pain patients. 
Self-monitoring was considered as a promising behavior in patients, but was not chosen as a 
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target because chronic persistence of this behavior, for example the use of a medication diary 
during a period of several months, is unlikely.
3. Specification of target behaviors
The selected target behaviors were specified as much as possible (see table 2). 
Table 2. Specification of target behavior
Target behavior Who needs to 
perform the 
behavior?
What do they 
have to do 
differently 
to achieve 
the desired 
behavior?
When do they 
need to do it?
Where do they 
need to do it?
how often do 
they need to 
do it?
With whom do 
they need to 
do it?
Share 
agreement on 
follow up policy
Medical Staff Agree and record 
how and how 
often follow up 
will take place.
After each 
contact
In the hospital, on 
the phone or by 
email.
After each 
contact
With the patient
Monitor 
medication 
adherence
Medical Staff Ask specifically 
about medication 
use
During each 
contact
In the hospital, on 
the phone or by 
email
During each 
contact
With the patient
Educate Patients Medical staff Organize 
educational 
interventions
After initiating 
pharmacological 
pain therapy
In the hospital Once a month Patients have 
to attend 
educational 
sessions
Discuss 
attitudes 
and concerns 
towards pain 
medication
Medical staff Actively discuss 
and register 
attitudes and 
concerns towards 
pain medication
During each 
contact
In the hospital During each 
contact
With the patient
habit formation Patient Combine 
medication 
taking with 
other automated 
habits (e.g. tooth 
brushing)
After initiating 
pain medication
At home Always Not dependent 
on others
use reminders 
to take 
medication
Patient Use any reminder 
to prevent 
forgetting 
medication
After initiating 
pain medication
Everywhere Always Not dependent 
on others
4. COM-b analysis: identify what needs to change
The next step was to use the COM-B model to analyze whether the targets of the interventions, 
caregivers and patients in this case, have the capability, opportunity and motivation to carry 
out the selected behaviors. In this step, a behavioral diagnosis for each target behavior was 
made by selecting COM-B components that need change to reach this behavior. This step was 
performed by four independent clinicians (including the first author) during a second consen-
sus meeting.
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In caregivers, psychological capability has to change by improving their relevant knowledge 
and skills to discuss medication use and apply adherence improving interventions. Every health 
care provider has to be aware of the magnitude of the problem of non-adherence and the 
importance of their eff orts to optimize medication use. As interventions cost time and eff ort, 
refl ective motivation is an important component to be maximized, as doctors should have the 
intention to apply the intervention consistently. Physical opportunity has to change to create 
a context in which the target behaviors can be performed easily (e.g. more time available for 
each patient visit; changes in patient data collection to ensure adequate attention for medica-
tion adherence). Social opportunity might need to be changed to apply selected interventions 
uniformly across a department to maximize the eff ects. This might, for example, be achieved 
by peer support. Automatic motivation needs to change to consistently ensure intervention 
application and create new routines.
In chronic pain patients, to support target behavior, some behavioral components might 
be changed. Psychological capability to use medication consequently with help of reminders 
and clues should be optimized. Refl ective motivation to take medication regularly and to use 
reminders consequently might need change. Associative learning using reminders and clues 
might induce automatic motivation. Finally, physical opportunity, consisting of resources to ap-
ply reminders (stickers, smartphone applications), is needed.
5. Identifi cation of intervention functions: how to achieve change?
This step, and all following steps, were performed by the authors, consisting of clinicians and 
a psychologist (DLS). Intervention functions considered in the BCW are: education, persua-
sion, incentivisation (e.g. by means of a reward), coercion, training, restriction, environmental 
restructuring (including changes in time schedules etc.), modelling (providing an example) and 
enablement (make it easier to perform a behavior). To make sure that proposed interventions 
would not only lead to a theoretical exercise but could actually applied in clinical practice, all 
intervention functions were evaluated with the APEASE criteria: Aff ordability, Practicability, 
(cost-) Eff ectiveness, acceptability, safety and equity (does the intervention type increase or 
decrease disparities between societal groups?). As we distinguished between target behaviors 
of medical staff  and those of patients, so we also distinguished between intervention functions 
aimed at behavior change of the medical staff  and that of patients. 
According to us, the most relevant functions to change caregivers behaviors are education 
of caregivers about the importance of adherence and relevant interventions to support ad-
herence and persuasion to perform the selected target behaviors. Furthermore environmental 
restructuring and enablement (e.g. by means of time, electronic aids) should support the perfor-
mance of adherence improving behaviors and strengthen refl ective and, eventually, automatic 
motivation of healthcare providers. Training how to perform adherence improving behaviors 
would be helpful, but is not practicable there is not enough time for all staff  members to follow 
training sessions. 
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In patients, we think that all intervention functions might generate the desired target be-
haviors (i.e., habit formation, use of reminders). The most relevant were patient education and 
persuasion to increase psychological capability and motivation to perform target behaviors, 
environmental restructuring and enablement to maximize automatic motivation to adhere to 
prescribed therapy. The use of coercion was considered unacceptable, and incentivisation was 
considered impracticable and not affordable on a large scale. 
6 . Identification of policy categories
In the next step, the BCW was used to select appropriate policy categories for each intervention 
function selected: what policies would enable the selected intervention functions to occur? 
Policy categories (legislation, service provision, regulation, fiscal measures, guidelines, commu-
nication and marketing, environmental and social planning) were evaluated with the APEASE 
criteria.
Policy selection depend upon the extend in which the interventions will be introduced: in 
one hospital or on a larger scale. Initially, the intervention should be evaluated on a small scale. 
The implementation should be communicated to the caregivers involved, and departmental 
guidelines about pharmacological pain therapy may support the performance of target behav-
iors. Provision of educational services for caregivers and patients are likely to be appropriate to 
increase capability and motivation. Finally, environmental planning consisting of changes in 
patient data management systems, scheduling of patient visits and introduction of reminder 
services, should be considered.
7. Identification of behavior change techniques
The authors discussed 93 items of the behavior change techniques taxonomyV1 (see also the 
smartphone app ‘BCTs taxonomy’ created by the ‘Center for Behavior Change’ of the University 
College London) and selected most relevant items from to be incorporated in the interventions.
For medical staff, we would suggest that improved psychological capability can be achieved 
by information about consequences of performing a target behavior (e.g. monitoring medica-
tion adherence), preferably from a credible source. Instruction on how to perform this behavior, 
goal setting (e.g. significant reduction of non-adherence within a year) and action planning 
(e.g. register adherence for every patient using analgesics from now on) regarding the inter-
vention components might be applied. Physical opportunity may be improved by adding 
objects, prompt or cues to the ‘environment’ (most importantly within the electronic patient data 
management system). Social opportunity might be improved by sharing commitment to the 
intervention with the entire health care team, including all senior staff members. Reflective 
motivation can be positively changed by sharing information about consequences of a preferred 
behavior, feedback on behavior, including its consequences. Most ideally, positive feedback 
(about reduction of non-adherence levels) following performance of target behaviors would 
stimulate persistence of these behaviors. Furthermore, reflective motivation should benefit 
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from enabling techniques that make the intervention easy to perform by changing the environ-
ment of caregivers. When an intervention is diffi  cult to perform, persistent use will be unlikely 
in daily practice. Automatic motivation will benefi t from BCTs such as habit formation and the 
addition of prompts and cues to the (electronic) environment. 
For patients, physical and psychological capability to form medication taking habits and use 
reminders to achieve this, can be improved by providing information about the consequences of 
the behavior, setting goals about medication adherence and providing instructions on how to 
use reminder tools and how to form habits. Physical opportunity should benefi t from changes 
in the patients’ environment e.g. addition of cues to take medication or reminders using smart-
phone applications, that a readily available nowadays. Social opportunity to take medication 
regularly might increase by support from family or relatives. Refl ective motivation requires 
information about consequences of medication. Automatic motivation requires the formation 
of medication taking habits, possibly supported by prompts or clues or other environmental 
changes. Finally, strong commitment to start, continue or restart the attempt to take the medi-
cation as prescribed is a prerequisite for medication adherence.
8. Identifi cation of modes of delivery
After identifying intervention content and policies for implementation, suitable modes of 
delivery (face-to-face delivery, for example group or individual counselling, or distant delivery, 
ranging from individual phone contact to large marketing campaigns) were selected by the 
authors for all parts of the intervention: 
Hospital staff 
Mode of delivery: face to face group sessions to educate and persuade prescribing health care 
providers to perform the target behaviors: share agreement on follow up; monitor medication 
adherence; educate patients; discuss attitudes and concerns towards pain medication by using the 
behavior change techniques as described above. Distant individual-level delivery of behavior 
change techniques might include required fi elds in the patient fi le regarding adherence mea-
surement and follow-up strategy. Furthermore, a prompt might be added to invite patients 
to pain education. Finally, target behaviors might be enabled by scheduling more time per 
patient. At distance population-level, providing educational and scientifi c articles about the 
importance of pain medication adherence might increase awareness of specifi c interventions. 
Clinical guidelines may suggest to restrict prescribing to patients that accept and receive edu-
cation and adherence monitoring.
Patients
Mode of delivery: face to face group sessions to educate and persuade patients to form habits 
of medication taking. Distant individual-level delivery of prompts/cues by SMS-reminders. 
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Another distant delivery to enable habit formation might be providing stickers, posters with 
text such as ‘did you take your medication?’ which can be used at home. 
InTERvEnTIOn DESIGn
We followed the step-by-step approach of the intervention design process as described by 
Michie et al, applying the COM-B model to the behavior of non-adherence to pain medica-
tion. We conclude with an intervention design that meets the APEASE criteria (affordability, 
practicability, (cost-) effectiveness, acceptability, side-effects (safety) and equity). 
The intervention consist of three parts, which are outlined in figure 4. First, prescribers should 
be informed and persuaded to preform adherence improving behaviors. Second, changes in 
patients data management systems should be made that maximally support these behaviors. 
Finally, patients receiving pain medication should be educated about their disease, its treat-
ment, the importance of medication adherence and the use of tools to support adherence 
behavior.
DISCuSSIOn
We applied the methodology of ‘the Behavior Change Wheel’ in order to design a theory based 
intervention to improve medication adherence in chronic pain patients. Earlier attempts with-
out thorough theoretical foundation have been shown to be unsuccessful.18,19 As medication 
adherence is a complex behavior and chronic pain is a complex multifactorial disease, there are 
many factors that may play a role in non-adherence behavior. Therefore, interventions should 
be tailored, at least partially, to the individual patient. 
After prioritizing and specifying target behaviors, making a behavioral diagnosis, identifying 
intervention functions, policy categories and behavior change techniques, there still remained 
multiple clues for interventions. Although this does not stroke with the ‘less is more principle’ 
as stated by the designers of the BCW, we wanted to propose an overarching intervention that 
included behavior change of patients as well as caregivers. The proposed intervention largely 
resembles strategies also described within the SIMPLE approach, a mnemonic for Simplifying 
regimen characteristics, Imparting knowledge, Modifying patient beliefs, Patient commu-
nication, Leaving the bias (of demographic factors) and Evaluating adherence.20 The SIMPLE 
approach provide a simplistic overview of methodologically proven adherence-enhancing 
strategies in general pharmacological therapy. Obviously, although pain medication adherence 
in chronic pain patients is complex behavior in a complex and heterogeneous patient category, 
pain adherence interventions should be based on the same principles. 
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Introduce mandatory registration fields into the patient data management system: 
a. Pain medication prescribed? Yes/no (if no, no further questions) 
b. Follow-up will take place within….. 
c. Did the patient attend pain education? (if no, please invite patient to an educational session) 
d. Medication adherence: 
i. took medication as prescribed 
ii. sometimes missed a dose 
iii. frequently missed a dose 
iv. sometimes took more medication than prescribed 
v. frequently took more medication than prescribed 
e. Please register any attitudes or concerns towards the use of pain medication. 
 
Organization of bi-annual educational sessions about pharmacological pain 
management and the importance of medication adherence for all staff of the pain 
treatment center, using selected Behavior Change Techniques.  
a. Explain the rationale of the intervention 
b. Explain intervention content 
i. share and register agreement on follow up of pharmacological 
therapy 
ii. monitor and register medication adherence 
iii. discuss and register attitudes and concerns towards pain medication 
iv. pharmacological treatment includes mandatory pain education 
v. enable the formation of habits 
vi. introduce the use of reminders 
c. Demonstrate the changes made in the patient data management system. 
d. Provide regular (bi-annual) feedback on behavior and its’ consequences. 
e. Commit the team to ensure improved use of pain medication. 
 
Organization of monthly pain education for patients about pain, pain medication 
and the importance of pain medication adherence, using selected Behavior 
Change Techniques.  
a. Explain adherence and the consequences of adherence to pain medication 
b. Interactively discuss common attitudes and concerns towards pain medication 
c. Discuss and demonstrate the use of reminders (smart-phone alarms, apps, stickers)  
d. Introduce clues to take medication 
e. Address regular adherence monitoring 
 
Evaluate behavior and consequences 
of behavior (non-adherence rates) 
and provide feedback to medical 
staff. 
Optional: if the intervention has 
proven successful, it may be 
embedded into a national guideline 
on pharmacological pain treatment to 
regulate further implementation. 
Summary 
- Introduce mandatory pain 
medication adherence fields into 
the PDMS 
- Organize medical staff schooling 
- Organize patient schooling 
- Evaluate and provide feedback 
figure 4. Flow-chart of a COM-B theory-based intervention in a pain treatment center to improve pain 
medication adherence.
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Many medication-adherence interventions have been focusing on the patient, in this analy-
sis however, most behavior changes have to be made by the healthcare providers. Proposed 
interventions focus largely on the health-care system. First, education of health care providers 
increases motivation and capability to perform the target behaviors by changing routines of 
medical prescription and follow-up strategies. Second, optimizing patient data management 
systems to increase the opportunity and motivation of caregivers to perform target behav-
iors, such as routine adherence monitoring, which has been shown effective in chronic pain 
patients.14 Finally, actual opportunity depends on time available to perform the required 
behaviors and possibilities to organize patient educational sessions routinely. 
Interventions to change patient behaviors also include patient tailored education, which 
should increase their capability as well as motivation to adhere to a prescription. However, 
patient motivation depends on more that knowledge alone. For example, intrinsic desires to 
self-management of health and active coping strategies, which are actually positive qualities of 
chronic pain patients, have been negatively associated with adherence. Nevertheless, adequate 
knowledge ensures that patients can make their own decisions regarding their treatment. 
Finally, introducing reminders to increase automatic motivation and capability has shown to 
be effective in increasing medication adherence.17 
The intervention proposal will be evaluated in a clinical trial, in which pre- and post-imple-
mentation data will be compared regarding predefined endpoints. Primary endpoint will be 
medication adherence according to self-report, secondary endpoints will include pain intensity 
and patient satisfaction. Furthermore, quantification of the impact of introduced changes on 
healthcare costs have to be made. The adherence intervention, which includes education and 
an intensified follow-up strategy, will cost time and result in increased treatment costs. At the 
same time, the intervention may result in savings due to improved treatment effect, timely 
cessation of unnecessary or ineffective medication and reduction of morbidity caused by non-
adherence.
A limitation of this study is that only four clinicians took part in a crucial step of this process: 
the selection of target behaviors to improve medication adherence. As the determinants of 
adherence in this population were systematically reviewed earlier, we chose to convert these 
into target behaviors with a limited team of pain physicians. Furthermore, although patient 
factors are frequently associated with medication adherence, we did not invite patients to 
participate in the selection process. Although the interventions account for some well-known 
patient factors, their contribution might have led to other insights. Finally, the final interven-
tion has not been tested for its impact in daily practice. Although the practical implementation 
consists of small changes in the data management systems and the introduction of educational 
sessions, the acceptability in terms of the recipients and those delivering the intervention is not 
accounted for. In our opinion, the intervention is comprehensive enough to actually work, and 
practicable enough to be used in clinical practice.
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We propose an adherence improving intervention that implies changes into the daily 
practice of pain medication prescription. Although large changes are generally unwanted in 
clinical practice, current prescription practices are often insuffi  cient to warrant adequate adher-
ence, which might cause sub-optimal treatment eff ect, healthcare costs and morbidity. The 
prescription of chronic pain medication should not be seen as the pain therapy but as a part of a 
treatment regimen including adequate follow-up, adherence monitoring and education during 
the course of the treatment. If shown to be eff ective, medication policies might be regulated 
by introducing prescription guidelines. This might improve medication adherence and reduce 
unnecessary pain medication taking.
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SuPPLEMEnTAL MATERIAL
Table S1. Selection of target behaviors to improve pain medication adherence. Selected target behaviors 
are presented in bold.
Potential target 
behaviors relevant 
to improve pain 
medication adherence
Impact of behavior 
change
Likelihood of changing 
behavior
Spillover score Measurement score
Avoid high dosing 
frequency
Promising Unpromising but worth 
considering
Unpromising but worth 
considering
Promising
Avoid polymedication Promising Unacceptable Unpromising but worth 
considering
Promising
Rethink prescribing pain 
medication in psychiatric 
patients
Promising Unpromising but worth 
considering
Unpromising but worth 
considering
Unpromising but worth 
considering
Rethink prescribing pain 
medication in patients 
with a history of drug 
abuse
Promising Unpromising but worth 
considering
Unpromising but worth 
considering
Unpromising but worth 
considering
Shared decision making Promising Unpromising but worth 
considering
Promising Unpromising but worth 
considering
Defi ne goal and time 
frame to reach goal
Promising Unpromising but worth 
considering
Promising Unpromising but worth 
considering
Share agreement on 
follow up policy
very promising very promising Promising Promising
Monitor medication 
adherence
very promising Promising Promising Promising
Educate patients Promising very promising very promising very promising
Discuss attitudes and 
concerns towards pain 
medication
very promising very promising very promising Promising
habit formation very promising very promising Promising unpromising but worth 
considering
use reminders to use 
medication
very promising Promising Promising Promising
Self-monitoring of 
medication adherence
Promising Unpromising but worth 
considering
Promising Very promising
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The aim of this thesis was to study medication adherence behaviour in chronic non-malignant 
pain patients to gain insight into its prevalence, factors contributing to adherence and poten-
tial interventions to optimize adherence behaviour. 
First, we performed a systematic review of the available literature to assess the prevalence 
and determinants of medication adherence in chronic pain patients. In a prospective cor-
relational study, we analysed the association between patient knowledge of their prescribed 
pain therapy and medication adherence. Following this study, we performed a randomized 
clinical trial examine if medication-specifi c educational intervention was able to increase pa-
tient knowledge and improve medication adherence. A second randomized clinical trial was 
performed to study the eff ect of three follow-up strategies on medication adherence and pain 
treatment satisfaction. In this latter study, we additionally focused on the associations between 
patients’ medication-related beliefs, and their medication adherence and pain treatment satis-
faction. Finally, using available empirical evidence, a psychological model of behaviour change 
was applied in order to design a theory-based intervention to improve medication adherence 
in chronic non-malignant pain patients.
This chapter comments on the main fi ndings of our work in relation to existing evidence and 
addresses some methodological challenges. The chapter closes by presenting some implica-
tions for daily practice and ideas for future research.
Medication adherence
The prevalence of medication non-adherence in chronic non-malignant pain is high: ap-
proximately 40 percent of patients does not adhere to prescribed therapy (chapter 2). In our 
studies, adherence rates ranged from 46 to 80 percent. This wide range is a refl ection of one of 
the diffi  culties in interpreting and comparing adherence research: there is no uniform way to 
operationalize adherence. In chapter 3, any deviation from prescribed therapy on the previous 
day was considered non-adherent behaviour. In chapter 4, we decided to use a diff erent, more 
realistic, defi nition to allow patients to miss a dose up to once a week over a larger time frame te 
be considered adherent. However, to increase reliability, we did combine it with a an additional 
screening tool to detect non-adherent behaviour. In chapter 5, the additional screening tool 
was left for practical reasons, which was thought to be acceptable because its results were 
shown to be strongly related to the other measure of adherence . 
Medication adherence is complex behaviour, as it:
- can be measured in various ways, using objective (e.g. urine analysis) or subjective (self-
report) methods.1,2
- can be defi ned in several ways (e.g. at least 80 percent of medication taken correctly)
- may change in time
- is dependent on several patient, provider and health system factors.3
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Although medication adherence is mostly presented dichotomously, additional gradations 
might be appropriate for a more detailed description of this behaviour.3 
Adherence rates in chronic pain patients were comparable to other chronic illnesses.3-5 
Although chronic pain is a symptomatic disease, presence of pain symptoms do not result in 
higher adherence rates compared to an asymptomatic disease as hypertension. The necessity 
and concerns framework provides a solid explanation for poor adherence to pain medication.6 
As chronic pain is a not life-threatening condition, patients may perceive their pain therapy as 
less important than other chronic therapies. Furthermore, pain medication is frequently associ-
ated with side-effects or symptoms of dependence, and patient may perceive the benefit-risk 
ratio as unsatisfactory.
Underuse of pain medication is more common than overuse.4,7 Medication overuse always 
has been an important concern in patients using pain medication and more specifically opioid 
medication, due to the risk of abuse, addiction and severe adverse events . However, although 
we found an association between opioid use and overuse, underuse is still more common in 
patients receiving opioid therapy.7 
Determinants of pain medication adherence
Patients may be non-adherent due to different beliefs, barriers and a range of other factors 
(chapter 2). Patients may intentionally decide not to take their medicines based on well-informed 
or mistaken beliefs about the benefits and risks of their medicines. Patients can unintentionally 
non-adhere to medicines due to forgetfulness, carelessness, health literacy and socioeconomic 
factors. 
Attitudes and concerns towards pain medication were found to be associated with certain 
patterns of adherence in chapter 6. These findings confirm earlier reports about the associations 
between medication-related beliefs and medication adherence in both chronic conditions in 
general as well as chronic pain specifically.6,8-10 Whereas the beliefs about Medicines Question-
naire (BMQ) has frequently been used to measure necessity beliefs and concerns in other chronic 
conditions 11,12, the Pain Medication Attitudes Questionnaire (PMAQ) is specifically designed for 
chronic pain management.9 Perceived need was positively associated with overuse. Concerns 
about side effects were positively associated with underuse non-adherence (chapter 6). The 
relation between patient beliefs about pain medication and their actual patterns of medica-
tion use might be of use in clinical practice. Addressing beliefs and concerns about medicines 
during patient counselling might identify patients at risk for non-adherence to medications. 
Although the original 47-item PMAQ might be unsuited for use in daily practice, the revised 
14-item PMAQ may be acceptable for routine use.13 In patients with low necessity beliefs or 
high level of concerns about prescribed therapy, the risk of non-adherence is considerable. In 
these patients, an informed and shared-decision regarding proposed therapy or alternative 
treatment might be considered to optimize treatment adherence and patient satisfaction.
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We found an association between knowledge of prescribed pain medication and adher-
ence to this medication (chapter 3). This association confi rmed earlier fi ndings, but was not 
confi rmed in the next trial, possibly due to methodological diff erences between both studies. 
Whereas patient education have been shown to improve medication adherence 14,15, our edu-
cational intervention did not (chapter 4). Our intervention was relatively simple and consisted 
of a single standardized video. Successful educational interventions were described to be more 
comprehensive and patient tailored.4 To be successful, educational interventions should not 
only be able to improve knowledge, but also increase motivation through assessment of exist-
ing beliefs about prescribed therapy.
A good relationship between patient and physician substantially improves adherence.3 Cen-
tralizing patient priorities, and addressing cultural belief and attitudes are important to reach a 
shared-decision regarding therapy.16 As time constraints limit the possibility to discuss patient 
beliefs about medications 17, we hypothesized that increasing follow-up frequency might lead 
to better medication adherence and treatment satisfaction. However, our study results did not 
support these thoughts (chapter 5). One of the reasons might be that the actual contents of 
the additional contacts were not controlled. If medication adherence and beliefs about pain 
medications were systematically addressed during each of the extra sessions, the results might 
have been diff erent. 
Medication adherence and treatment outcome
Medication adherence has been shown to have a signifi cant eff ect on therapy outcome and 
health care costs in chronic illnesses.18 In chronic pain, however, this relationship is less clear. 
Some studies demonstrate an association between pain medication and treatment outcome 
19,20, other do not.10,21,22 There are some explanations that are partly methodological and partly 
due to the nature of chronic pain. Therapy outcome is mostly reported by means of pain inten-
sity levels. Pain intensity has been associated with adherence in both directions (chapter 2). If 
there is little or no pain, patients may feel pain medication unnecessary. High pain levels may be 
interpreted as a higher need for pain medication, and may therefore lead to better adherence 
or even overuse of pain medication. On the other hand, patients who do not use their medica-
tions may have higher pain intensities than patients that use their prescription correctly. This 
explains the variety of relationships reported between pain intensity and treatment outcome 
in chapter 2. We did not fi nd a relationship between medication adherence and pain intensities 
in our studies. In our last trial, we intentionally defi ned treatment outcome diff erently by using 
the Pain Treatment Satisfaction Scale. The fact that we still did not fi nd a relationship between 
adherence and outcome might be caused by the low number of patients that were actually 
non-adherent in this study. 
The question rises if it is important to pursue adherent behaviour in chronic pain by means 
of adherence-improving interventions when a causal relationship between medication 
adherence and outcome has not been found. However, besides the reasonable assumption 
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that some adherence is necessary for medication to work, non-adherence leads to an inability 
to accurately assess the effect of prescribed therapy, and might lead to unnecessary visits or 
therapy changes. Furthermore, incorrect pain medication use, especially overuse, might lead 
to health risks. 
Interventions
The high levels of non-adherence in chronic illnesses indicate a definite need to intervene. Suc-
cessful interventions have been shown to be complex and multifactorial, and often difficult to 
implement in clinical practice. However, our studies demonstrate that limited interventions, us-
ing small parts of effective complex interventions, were unsuccessful, as were other studies in 
chronic non-malignant pain patients.23 In the last chapter, we used a theoretical framework and 
available evidence on pain medication adherence to design an intervention that is comprehen-
sive enough to be effective, targeting multiple factors affecting adherence, without unaccept-
able changes that couldn’t be applied in clinical practice. The most important conclusion of this 
approach was that the key focus of the intervention should be the health care provider, instead 
of the patient. The finding that providers spend less than a minute to discuss all aspects of new 
prescription medications, indicates that there might be a need for restructuring prescribing 
practices.17 The health care team should be committed to bring pharmacological pain manage-
ment to a higher level, implementing the possible steps described in chapter 7. 
Implications for future research and clinical practice
In chronic pain management the prevalence and determinants of medication non-adherence 
are well-investigated. However, although validated measures of medication adherence exist, 
it would be helpful to reach consensus about how to define and validly measure adherence 
in the chronic pain population. Furthermore, a prospective study using validated measures of 
pain treatment outcome, might further elucidate the relationship between medication adher-
ence and outcome. Finally, new adherence-improving interventions have to be designed and 
studied for its effect on medication use. 
In conclusion, the magnitude of the problem of non-adherence in chronic non-malignant 
pain patients is high. Therefore, it deserves appropriate attention from all stakeholders involved. 
Although medication adherence concerns patients’ behaviours, the health care providers carry 
an important responsibility to provide optimal conditions for patients to adhere to their recom-
mendations. The findings in this thesis demonstrate that proper patient selection for pharma-
cological pain therapy should include a basic risk factor screening for non-adherence and an 
open discussion about the views of patients about the proposed therapy. An optimal strategy 
for ensuring adequate adherence has not been found, and might not exist for a large group 
of patients. However, each individual prescription of chronic pharmacological pain therapy 
should include efforts to promote optimal medication adherence. 
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In chapter 1, the rationale for this thesis is described. Chronic pain is a common chronic con-
dition which is frequently treated with the prescription of pain medication. Non-adherence 
to prescribed medication is common and may account for sub-optimal treatment results. 
Although many reports have described determinants of medication adherence in chronic pain 
patients, these have not been translated into successful interventions to improve it. The aim 
of the work presented in this thesis was to explore the concept of medication adherence in 
chronic non-malignant pain patients in order to design eff ective interventions to improve the 
use of prescribed pain therapy.
Chapter 2 describes the results of a systematic review of the prevalence and determinants 
of medication non-adherence in chronic pain patients. In the twenty-fi ve studies reviewed, a 
mean of forty percent did not use their medication as prescribed. Underuse of medication was 
more common than overuse. Factors associated with non-adherence in general, and underuse 
and overuse specifi cally, are presented. To improve medication adherence, these risk factors 
should be taken into account when prescribing pharmacological pain therapy. 
In chapter 3, the results of a prospective observational study of the association between 
knowledge and adherence to a pharmacological prescription in patients with chronic non-
malignant pain are presented. Basic knowledge of pain medication was found to be low and 
did not improve during the course of the study. Knowledge of the prescription was found to be 
associated with adherence to this prescription. 
Following this study, we designed an educational intervention aimed at improving medica-
tion adherence. The eff ect of this intervention was investigated in a randomized clinical trial 
described in chapter 4. Although standardized information about prescribed therapy did in-
crease knowledge about this therapy, it did not change medication adherence or treatment 
outcome parameters. 
We hypothesized that an increased number of contacts during follow-up of pharmacological 
therapy would improve medication adherence. Chapter 5 describes the results of a random-
ized controlled trial to compare the eff ect of three diff erent follow-up strategies on medication 
adherence, therapy outcome and health care consumption in chronic non-malignant pain 
patients: (1) standard care, (2) intensive hospital-initiated follow-up, in which patients were 
contacted every two weeks, and (3) intensive patient-initiated follow-up, in which patients 
received standard care and additional follow-up on demand. No diff erences were found in 
medication adherence. Patient initiated care did not lead to increased number of unplanned 
contacts. Although patient satisfaction regarding the provision of information was higher in 
both the intensive hospital- and patient initiated follow-up groups, other outcomes did not 
diff er. 
In Chapter 6, a prospective investigation of the relation between patients’ beliefs about pain 
medication and their medication adherence and treatment outcome is presented. Concerns 
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over side effects at baseline were positively associated with underuse after 11 weeks. Perceived 
need was positively associated with overuse. Concerns over side effects and mistrust in the 
doctor at baseline were negatively associated with patient satisfaction regarding prescribed 
medication after 11 weeks, and concerns over side effects and concerns over withdrawal were 
positively associated with presence of side effects after 11 weeks. This chapter discusses the 
importance of taking patients’ beliefs about medication into account when prescribing pain 
medication.
Chapter 7 describes the use of a theoretical psychological model of behaviour change in 
order to design an intervention to improve medication adherence in chronic pain patients. An 
important finding is that most interventions should be focused on providers of pain therapy. 
The proposed intervention consist of three elements: (1) changes in the patient data manage-
ment systems to facilitate adherence monitoring, (2) repeated education of medical staff to 
commit the team to the proposed intervention and (3) routine and mandatory education of 
chronic pain patients following prescription of pain medication. 
In the general discussion in chapter 8, the main findings of this thesis are discussed. It 
presents recommendations for future studies of pain medication adherence in chronic pain 
patients. It re-emphasises the importance of screening for risk factors of non-adherence when 
prescribing pharmacological pain therapy. The chapter concludes with the statement that, 
although an optimal strategy for ensuring adequate adherence has not been found, and might 
not exist for a large group of patients, each individual prescription of chronic pharmacological 
pain therapy should include efforts to promote optimal medication adherence.
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In de introductie in hoofdstuk 1 worden de achtergronden bij dit proefschrift beschreven. 
Chronische pijn is een veel voorkomende chronische ziekte. De behandeling bestaat vaak uit 
het voorschrijven van pijnmedicatie. Gebrek aan therapietrouw komt vaak voor en kan een 
verklaring zijn voor de gebrekkige resultaten van de behandeling. Ondanks dat er veel deter-
minanten beschreven zijn van medicatietrouw van patiënten met chronische pijn, zijn deze 
nog niet vertaald in eff ectieve interventies on deze trouw te verbeteren. Het doel van het on-
derzoek beschreven in dit proefschrift was om een beter inzicht te krijgen in de therapietrouw 
van patiënten met chronische benigne pijn om zo eff ectieve interventies te ontwerpen om het 
gebruik van pijnmedicatie te verbeteren. 
In hoofdstuk 2 worden de resultaten beschreven van een systematische review van studies 
naar de prevalentie en determinanten van medicatie-ontrouw bij patiënten met chronische 
pijn. In de 25 geselecteerde studies gebruikte gemiddeld 40 procent van de patiënten de 
medicatie niet zoals voorgeschreven. Ondergebruik van pijnmedicatie kwam vaker voor dan 
overgebruik . Factoren die geassocieerd zijn met medicatietrouw in het algemeen, of die spe-
cifi ek met ondergebruik of overgebruik gerelateerd zijn, worden in dit hoofdstuk beschreven. 
Om medicatietrouw te verbeteren is het goed dat men rekening houdt met deze factoren bij 
het voorschrijven van een medicamenteuze pijnbehandeling.
In hoofdstuk 3 worden de resultaten van een prospectieve observationele studie naar de 
relatie tussen kennis van - en trouw aan een voorschrift voor pijnmedicatie uiteengezet. Basale 
kennis van pijnmedicatie was laag en nam niet toe gedurende de looptijd van de studie. Kennis 
van het specifi eke voorschrift was geassocieerd met trouw aan dit voorschrift.
Na deze studie werd in een gerandomiseerde gecontroleerde studie onderzocht of gestan-
daardiseerde educatie over het specifi eke voorschrift de trouw aan dit voorschrift zou verbete-
ren. De resultaten worden beschreven in hoofdstuk 4. Ondanks dat de educatieve interventie 
over het voorgeschreven pijnmedicijn de kennis van het voorschrift verbeterde, trad geen 
verandering op in medicatietrouw of uitkomst van de behandeling.
Onze hypothese was dat een toename van het aantal patiëntcontacten gedurende de follow-
up van farmacologische pijnbehandeling de therapietrouw zou verbeteren. In hoofdstuk 5 
worden de resultaten van een gerandomiseerde gecontroleerde studie beschreven waarin het 
eff ect van drie verschillende follow-up strategieën worden vergeleken op medicatietrouw: (1) 
standaard zorg, (2) intensieve ziekenhuis-geïnitieerde follow-up, waarbij patiënten elke twee 
weken werden opgevolgd, en (3) intensieve patiënt-geïnitieerde follow-up, waarbij patiënten 
naast standaard zorg op ieder moment aanvullende aandacht konden krijgen. Er werd geen 
verschil in medicatietrouw gevonden tussen de drie groepen. Patiënt-geïnitieerde follow-up 
leidde niet tot meer ongeplande contacten. Ondanks dat de tevredenheid van patiënten over 
de informatieverschaffi  ng hoger was in zowel de intensieve ziekenhuis- als patiënt-geïnitieerde 
follow-up groep, waren overige tevredenheidsscores niet verschillend.
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In hoofdstuk 6 worden de resultaten van een prospectief onderzoek naar de relatie tussen 
gedachtes van patiënten over pijnmedicatie, hun medicatietrouw en behandeluitkomsten 
besproken. Angst voor mogelijke bijwerkingen voorafgaand aan de behandeling was positief 
geassocieerd met ondergebruik van pijnmedicatie na 11 weken. Een ervaren behoefte aan pijn-
medicatie was positief geassocieerd met overgebruik. Angst voor bijwerkingen en gebrek aan 
vertrouwen in de behandelaar voorafgaand aan de behandeling waren negatief geassocieerd 
met tevredenheid over het voorgeschreven medicijn na 11 weken. Angst voor bijwerkingen 
en angst voor onttrekkingsverschijnselen waren positief geassocieerd met het daadwerkelijk 
optreden van bijwerkingen na 11 weken. Dit hoofdstuk onderstreept dat het van belang is 
rekening te houden met de gedachtes van de patiënt over pijnmedicatie als gekozen wordt 
voor een medicamenteuze pijnbehandeling.
In hoofdstuk 7 wordt beschreven hoe een theoretisch model van gedragsverandering 
gebruikt wordt om een interventie te ontwerpen die medicatietrouw van patiënten met 
chronische pijn kan verbeteren. Een belangrijke constatering is dat interventies vooral op de 
zorgverlener gericht moeten zijn. De voorgestelde interventie bestaat uit drie onderdelen: 
(1) veranderingen in het elektronische patiëntendossier die monitoring van medicatietrouw 
ondersteunen, (2) herhaalde scholing van zorgverleners voor maximale en eensgezinde be-
trokkenheid bij de voorgestelde interventie en (3) routinematige en verplichte scholing voor 
patiënten met chronische pijn nadat gestart is met medicamenteuze pijnbehandeling.
In hoofdstuk 8 wordt nader ingegaan op de belangrijkste bevindingen uit dit proefschrift. 
Er worden aanbevelingen gegeven voor toekomstige studies op het gebied van medicatie-
trouw bij patiënten met chronische pijn. Opnieuw wordt benadrukt dat het belangrijk is om 
een inschatting te maken van het risico op medicatie-ontrouw als nieuwe medicatie wordt 
voorgeschreven. Het hoofdstuk eindigt met de stellingname dat, ondanks dat een optimale 
strategie om medicatietrouw te bevorderen niet werd gevonden, en mogelijk niet bestaat voor 
deze patiëntengroep als geheel, ieder individueel voorschrift van pijnmedicatie gepaard zou 
moeten gaan met inspanningen om optimale therapietrouw te bevorderen.
APPEnDICES
Dankwoord 
Curriculum Vitae 
PhD portfolio 
Publications
141
Dankwoord
A
 DAnkWOORD
In de afgelopen jaren hebben veel mensen bijgedragen aan de totstandkoming van dit proef-
schrift. Ik wil alle collega’s, vrienden en familie danken hiervoor. Jullie hulp bij het onderzoek, 
de motiverende of relativerende gesprekken en jullie gezelschap waren en zijn belangrijk voor 
me. Enkele mensen wil ik graag ik het bijzonder bedanken.
Mijn promotor, professor Huygen. Beste Frank, hartelijk dank voor de mogelijkheid om dit 
promotieonderzoek te doen bij het Centrum voor Pijngeneeskunde. Bedankt voor het vertrou-
wen, je geduld en je doortastendheid op de momenten dat het nodig was. Toen we elkaar 
voor het eerst spraken gaf je aan dat je van het doen van wetenschappelijk onderzoek ook een 
betere dokter kon worden. Ik was niet overtuigd en zag wetenschap en kliniek toch een beetje 
los van elkaar. Mijn mening hierover is veranderd. 
Mijn copromotor, dr. Stronks. Beste Dirk, zonder jou was het nooit gelukt. Dank voor al je hulp 
en geduld. Ik heb enorm veel geleerd van je streven naar methodologische perfectie, ondanks 
het feit dat deze soms niet bestaat. Ik had me geen betere copromotor kunnen wensen.
Dr. J.G. Groeneweg. Beste George, hartelijk dank voor je hulp bij de studies, de begeleiding 
op meerdere fronten en alle adviezen tijdens mijn promotietraject. 
De onderzoeksgroep van het Centrum voor Pijngeneeskunde. Dank voor het feit dat ik, 
ondanks het feit dat ik niet vaak aanwezig was, altijd welkom werd ontvangen en uitgenodigd 
werd op evenementen. Nadia Kriek, bedankt voor je hulp met de vragenlijsten. Anita van Toor, 
bedankt voor de coördinatie van alle afspraken en je fl itsende reactie op emails.
De leescommissie. Professor Van Busschbach, professor Knibbe, en professor Bindels, harte-
lijk dank voor de beoordeling van mijn proefschrift.
Mijn maatschap. Een betere steun in de rug bestaat er niet. Ik hoefde het woord onderzoek 
maar te noemen en mijn taken werden overgenomen, ook in het zesde achtereenvolgende 
jaar. Ik ben blij dat, ondanks de groter geworden groep, werk voelt als een tweede thuis. 
Marcel, bedankt voor het bewaken van de organisatorische rust. Marja, bedankt voor je be-
reidheid om altijd te willen helpen waar nodig. Ingeborg, ik ben blij dat jij op een enthousiaste 
manier de stabiele factor voor de wetenschappelijke ambities van onze maatschap bent. Ik 
ben er trots op wat wij als maatschap met zijn allen bereikt hebben en zie uit naar wat nog 
komen gaat. In het bijzonder wil ook mijn collega pijnspecialisten bedanken voor hun bijdrage 
aan mijn studies. Liong Liem, Jack Poell, Eric van Dongen, Harold Nijhuis, Willem-Jan Hofste, 
Sjoerd van Egeraat, Imre Krabbenbos, Wafa Rezvani en Joep Scholten, bedankt voor alle hulp! 
Pijnconsulenten en doktersassistenten, het informeren van patiënten, de coördinatie van 
alle afspraken en alle telefonische follow-up contacten werd door jullie verricht. Jullie waren 
onmisbaar. 
Mijn vrienden wil ik bedanken voor hun interesse, steun en vooral vriendschap. Jelmer, 
Willem-Peter, Maarten, Lahcen, Dimitri, Peter en Roeland, bedankt voor jullie pep-talks en 
steun. Ook al zien we elkaar niet meer dagelijks, het voelt altijd alsof we doorgaan met een 
APPENDICES
142
gesprek dat we gisteren gestopt zijn. Arthur, Danny, Allard, Sander, Michel, dank voor het feit 
dat jullie nooit over werk, onderzoek of promoties praten.
Mijn paranimfen. Peter Noordzij. Peet, na onze studententijd, met onze jaarclub, onze geza-
menlijke Marmotte, en nu samen in een maatschap, voelt het vertrouwd dat je naast me staat 
tijdens mijn promotie. Ik kan je niet genoeg bedanken voor je advies om te focussen. Roeland 
Riedijk. Roeland, terugverlangen naar onze studiejaren gaat te ver, maar ik mis de woensdagen 
in de jaren dat je mijn buurman was in Zeist wel een beetje. Ik ben blij dat je nog een keer naast 
me komt staan. Dank!
Ook mijn familie wil ik graag bedanken. Mamma, dank voor je steun, je interesse en ook je 
bezorgdheid. Je hebt je misschien stiekem wel eens afgevraagd waarom het allemaal nodig 
was. Pappa, wat jammer dat je er niet meer bij kan zijn, wat had ik dit graag met je gedeeld. 
Mirjam, bedankt voor je luisterende oor, je nuchtere mening en je adviezen als ik deze nodig 
heb. Ik zal nooit meer met werk bezig zijn tijdens de wintersport, dat beloof ik.
Tot slot wil ik mijn gezin bedanken. Lieve Suus, dank dat je me de onvoorwaardelijke steun en 
liefde hebt gegeven om dit proefschrift te schrijven. Het heeft veel avonduren en energie van 
ons allebei gekost. Ik was blij dat je af en toe ook aan de noodrem trok. Lieve Julia en Stefan, ik 
ben jullie hele leven met dit proefschrift bezig geweest. Bedankt voor jullie vrolijke afleiding en 
relativerende capaciteiten. Ik hou van jullie.
143
Curriculum vitae
A
 CuRRICuLuM vITAE
Leon Timmerman werd geboren op 29 oktober 1975 te Rotterdam. Hij behaalde zijn gymna-
sium-diploma aan het Caland Lyceum te Rotterdam. In 1994 is hij begonnen aan de studie 
Geneeskunde aan de Erasmus Universiteit in Rotterdam. Het doctoraalexamen werd behaald 
in 1998 en het artsexamen werd afgerond in april 2001.
Na het afronden van zijn geneeskunde opleiding heeft hij van 2001 tot 2003 twee jaar 
ervaring opgedaan als assistent geneeskundige niet in opleiding (AGNIO) op de afdelingen 
interne geneeskunde, longziekten en cardiologie van het Zuiderziekenhuis in Rotterdam. In 
2003 startte hij met de opleiding tot anesthesioloog in het Sint Antonius Ziekenhuis in Nieuwe-
gein (opleider: Dr. H.P.A. van Dongen). In het laatste jaar van de opleiding richtte hij zich op het 
aandachtsgebied pijngeneeskunde. Na afronding van de opleiding werkte hij van april 2008 tot 
en met december 2009 in het Medisch Centrum Haaglanden in Den Haag als anesthesioloog-
pijnspecialist. Sinds januari 2010 is hij werkzaam als anesthesioloog-pijnspecialist in het Sint 
Antonius Ziekenhuis in Nieuwegein.
Sinds 2010 is hij geregistreerd in het aandachtsgebied Pijngeneeskunde. In 2011 werd ge-
start met het onderzoek dat tot dit proefschrift heeft geleid.
Leon woont samen met Suzanne en hun kinderen Julia en Stefan in Zeist.
145
PhD portfolio
A
 PhD PORTfOLIO
Name PhD student: Leon Timmerman  PhD period: 2011-2017
St. Antonius Hospital   Promotor: Prof. dr. F.J.P.M. Huygen
Department of Anesthesiology,  Co-promotor: Dr. D.L. Stronks
Intensive Care and Pain Medicine
1. PhD training
Courses
BROK- course 2016
SPSS and Medical Statistics basic course 2012
Conferences
Annual congress on pain, Den Bosch 2016
Annual congress on pain, Utrecht 2015
Annual congress on pain, Brugge 2013
Third biannual international pain congress, Middelburg 2012
7th congress of the European Federation of IASP chapters, Hamburg 2011
Masterclass neuropathic pain, Rotterdam 2011
2. Teaching
Bi-monthly education for chronic pain patients: ‘Chronic pain and pain treatment’.
Presentation for the Dutch Society of Occupational Experts 2016: ‘Pain and Work’.
Regional course residents anesthesiology 2016: ‘Pharmacological pain management and medi-
cation adherence’.
Regional course residents anesthesiology 2014: ‘Low back pain in the elderly patient’.
Regional course residents anesthesiology 2012: ‘Awareness and monitoring of anesthetic 
depth’.
Post-graduate course pharmacology 2011: ‘Pain management at the Emergency Department’.
Course General Practitioners ‘duodagen’ 2011: ‘Advanced pain management’
Regional course residents anesthesiology 2010: ‘Inhalational anesthetics’
APPENDICES
146
3. Abstracts and presentations
Ramsodit P, Timmerman L. The Effect of Clonidine As An Additive to Local Anaesthetics On the 
Duration of Postoperative Analgesia After Orthopaedic Foot Surgery: A Randomized Clinical 
Trial. P. Anesth Analg 2016; 123(3S_Suppl 2): 647-48.
L. Timmerman, DL Stronks, JG Groeneweg, FJPM Huygen. Prevalence and determinants of 
medication non-adherence in chronic pain patients: a systematic review. Annual scientific 
meeting Dutch Society of Anesthesiology 2016, Rotterdam.
L. Timmerman, DL Stronks, JG Groeneweg, FJPM Huygen. Medication adherence and treatment 
outcome in patients with chronic pain. Scientific meeting department of Anesthesiology, 
Erasmus MC Rotterdam.
L. Timmerman, DL Stronks, JG Groeneweg, FJPM Huygen. The value of medication-specific DVD-
information on medication adherence and treatment outcome in patients with chronic pain: a 
randomized clinical trial. Annual scientific meeting Dutch Society of Anesthesiology 2014, Zeist. 
Brackel AML, Marting LN, Timmerman L. Comparison of local infiltration analgesia with epidural 
analgesia after total knee arthroplasty: a randomized clinical trial (NCT01489631). Annual sci-
entific meeting Dutch Society of Anesthesiology 2014, Zeist.
L. Timmerman, R Stellema, DL Stronks, JG Groeneweg, FJPM Huygen Adherence to pharmaco-
logical pain therapy in patients with non-malignant pain: the role of patients’ knowledge of 
pain medication. Annual scientific meeting Dutch Society of Anesthesiology 2013, Zeist. 
Articaine and lidocaine for spinal anesthesia in day-case surgery.L Timmerman, EP van Dongen, 
E Tromp, EJM Andriessen, CAJ Knibbe. XXIV Congress of the European Society of Regional 
Anaesthesia and Pain Therapy, Valencia 2007 en 7th International Congress on Ambulatory 
Surgery, Amsterdam 2007.
Perifere zenuwstimulatie voor pijn na traumatisch zenuwletsel.
L Timmerman, AL Liem.
Voorjaarsvergadering Nederlandse Vereniging voor Plastische Chirurgie, Utrecht 2007.
Peripheral nerve stimulation for intractable pain.
L Timmerman, AL Liem.
World Institute of Pain congress 2004, Barcelona.
147
PhD portfolio
A
4. Studies
2011-2013: STRIDE study: A Multicentre, Single-Arm, Open-Label Study of the Repeated Admin-
istration of QUTENZATM for the Treatment of Peripheral Neuropathic Pain. Principal Investigator.
2012-2014: PAINTHER study: The value of medication-specifi c DVD-information on medication 
adherence and treatment outcome in patients with chronic pain: a randomized clinical trial. 
Principal Investigator.
2013-2014: ANALGESIETKP: Comparison of intra-articular infi ltration and gabapentine with 
epidural analgesia after total knee replacement surgery: a randomized clinical trial”. Principal 
Investigator.
2014-2016: PANTHER II study: The eff ect of hospital-initiated and patient-initiated intensive 
follow-up on medication adherence in patients with chronic pain: a randomized controlled 
clinical trial. Principal Investigator.
2015-2017: CALPAFAS: The eff ect of clonidine as additive to local anaesthetics on duration of 
postoperative analgesia after orthopaedic foot surgery: a randomized clinical trial. Investigator.
2016 - present: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to 
Evaluate the Effi  cacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosa-
cral Radiculopathy. Principal Investigator. 
2017-present: EFIC PAIN OUT project: Optimizing management of perioperative pain in Europe. 
Principal Investigator.
5. Other
2015  Winnaar ‘St Antonius uitkomstprijs’ voor reductie postoperatieve pijn, uitgereikt 
tijdens symposium ‘Uitkomsten van onze Zorg’.
149
Publications
A
 PubLICATIOnS
Papers related to this thesis
Timmerman L, Stronks DL, Groeneweg JG, Huygen FJPM. The value of medication-specifi c 
education on medication adherence and treatment outcome in patients with chronic pain: a 
randomized clinical trial. Pain Med. 2016 Oct;17:1829-1837. 
Timmerman L, Stronks DL, Groeneweg JG, Huygen FJPM. Prevalence and determinants of medi-
cation non-adherence in chronic pain patients: a systematic review. Acta Anaesthesiol Scand 
2016; 60(4): 416-31.
Timmerman L, Stellema R, Stronks DL, Groeneweg JG, Huygen FJPM. Adherence to pharmaco-
logical pain therapy in patients with non-malignant pain: the role of patients’ knowledge. Pain 
Pract 2014; 14: 701-8.
Timmerman L, Stronks DL, Huygen FJPM. The design of a theory-based intervention to improve 
medication adherence in chronic pain patients. Curr Med Res Opin. 2017;33:1293-1301.
Timmerman L, Stronks DL, Groeneweg JG, Huygen FJPM. Comparison of the eff ect of intensi-
fi ed hospital-initiated follow-up, patient-initiated follow-up and standard care on medication 
adherence in patients with chronic pain: a randomized controlled clinical trial. Submitted
Timmerman L, Stronks DL, Groeneweg JG, Huygen FJPM. The relation between patients’ at-
titudes towards pain medication and their medication adherence and treatment outcome in 
chronic pain patients: a prospective study. Submitted
Papers not related to this thesis
Timmerman L, Megens HAM. Detecting intravascular injection during caudal anesthesia in 
children. Eur J Anaesthesiol 2007; 24(10): 1060-2. 
Brackel AML, Timmerman L. Anesthesie bij plaatsing van een Totale Knieprothese. Anesthesi-
ologie en Intensive Care 2014 (3): 21-25.
Liem AL, Timmerman L. A new approach to neurostimulation for peripheral pain. 
Puesta al dia en anestesia regional y tratamiento del dolor 2006; 9:235-237.
Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO, Trapman J. 
Broadened ligand receptor responsiveness of androgen receptor mutants obtained by random 
APPENDICES
150
amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 
2002; 20;100:309-17.
book chapters
Timmerman L, Huygen FJPM. Chronische medicamenteuze pijnbehandeling. In: P.J. Hennis, 
H.P.A. van Dongen, W.A. van Klei. Leerboek anesthesiologie. Houten: Uitgeverij Bohn Stafleu 
van Loghum 2013. Hoofdstuk 47.
Timmerman L. Hart en circulatie. In: P.G. Noordzij, M. Klimek en J.J. Landman. Klinische anesthe-
siologie. Utrecht: Uitgeverij de Tijdstroom 2017. Hoofdstuk 5.
